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ABSTRACT 
The use of nanoparticles for disease treatment is an increasingly popular area of research. 
The potential for multi-functionality allows nanoparticles to be used as transport and delivery 
vehicles for drugs and as diagnostic aides, among other applications, to address the unmet needs 
of many disease treatments. One such class of disease is osteoporosis including severe disorders, 
like Paget’s disease, Osteogenesis Imperfecta and Legg Calve Perthes disease. In this dissertation, 
we discuss a nanoparticle system consisting of gold nanoparticles surface functionalized with 
primary amine bisphosphonates, which is a classification of pharmaceuticals that is common in 
the treatment of osteoporosis. Functionalized nanoparticles allow for greater intracellular 
concentrations of pharmaceutical, while the properties of the gold nanoparticles provide the ability 
to track the pharmaceutical and enhance imaging. 
We have synthesized and characterized bisphosphonate functionalized gold nanoparticles 
of controlled size of approximately 15 nm, which are suitable for cellular uptake, and 
functionalized the surface using self-assembly with pamidronate and alendronate. In one major 
finding of this study, inductively coupled plasma mass spectrometry was used to estimate 
approximate surface density of the bisphosphonates on the gold nanoparticles. This resulted in 
concentrations of approximately 0.65 molecules per nm2 (approximately 154 Å2/molecule) for 
pamidronate functionalized on gold, and approximately 2.6 molecules per nm2 (approximately 39 
Å2/molecule) for alendronate functionalized on gold. This allows for more accurate estimates of 
pharmaceutical concentrations, during in vitro and in vivo studies.  
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Additionally, we investigated the effects of bisphosphonate functionalized gold 
nanoparticles on the viability and morphology of osteoclast and osteoblast cells in vitro. We found 
that attaching the bisphosphonates to the surface of the nanoparticles leads to increased apoptotic 
effects of the bisphosphonates on the osteoclast cells compared to free bisphosphonates. Further, 
we showed bisphosphonate functionalized gold nanoparticles may have an effect on nuclei 
morphology that may provide an additional means of modulating bone resorption rather than just 
through influencing viability. Further we showed that it may be possible to target concentrations 
that are safe for osteoblasts, which is critical in determining potential treatment concentrations. 
These viability results bring to light a number of potential considerations into the optimization of 
potential treatments, such as dosing concentrations.   
Finally, detailed results are given on effects of bisphosphonate functionalized gold 
nanoparticles on important behavior and activity of osteoclast and osteoblast cells in vitro. We 
showed that while using concentrations below the toxicity threshold, some of the normal activity 
of the cells could be maintained. RANKL and ALP expression in osteoblasts were maintained 
when removing viability as a variable. Additionally, bone nodule formation was also maintained 
for osteoblasts and co-cultured in vitro systems. Finally, we showed that the introduction of bone 
in the in vitro studies adds a new degree of consideration as to the interaction of the 
bisphosphonates with the hydroxyapatite surface. This strong interaction with bone is an important 
consideration in further developing potential treatments for osteoporotic disease. 
This dissertation provides insights into the use of bisphosphonate functionalized gold 
nanoparticles as a potential treatment and means of study for bone remodeling disorders.  
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CHAPTER 1: 
INTRODUCTION1 
The research described in this dissertation focuses on the study and development of a novel 
nanoparticle based system as a potential treatment and means of study for severe osteoporotic 
diseases. Towards that end, a brief overview of bone as an organ, as well as the bone remodeling 
processes is presented in order to provide context for osteoporotic disorders. Additionally, a brief 
description of the standard treatment for osteoporotic disorders is provided as this treatment is 
usually a common yardstick when developing new treatments. Towards the main research goal, an 
introduction to nanoparticles is given, with a focus on gold nanoparticles, and the properties that 
make them attractive for various biomedical applications, especially drug delivery and medical 
imaging.  
1.1 Bone 
Bone is a large, complex organ that makes up the skeleton and is responsible predominantly 
for the support and protection of various organs in the body while enabling mobility by acting as 
attachment points for muscles, tendons, and ligaments[1]. Bone also acts as a storehouse for 
various minerals (like calcium and phosphorus), and is responsible for the production of red and 
white blood cells. It is a relative light, but dense hybrid of an active tissue of different cells 
supported by mineralized osseous tissue. These cells include osteoblast and osteoclasts, which are 
1 Part of this chapter was published in Conners, Christopher M., Bhethanabotla, Venkat R., and Gupta, Vinay K. 
(2015). "Concentration-dependent effects of alendronate and pamidronate functionalized gold nanoparticles on 
osteoclast and osteoblast viability." J Biomed Mater Res B. Permission is included in Appendix B. 
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responsible for bone mineralization and resorption respectively, whereas the osseous tissue is made 
up of various inorganic salts as well as collagen[2]. A mature adult will possess approximately 206 
[3] separate bones made up of five different types of bone: long, short, flat, sesamoid, and irregular. 
Bone has a layered structure made up of the outer cortical bone surrounding inner cancellous bone, 
which itself typically contains bone marrow (Figure 1.1). 
 Cortical bone is relatively hard due to its higher density than cancellous bone, lending to 
it also being known as compact bone. This outer layer is what gives bones their outward 
appearance and represents approximately 80% by mass of all bone in adults. It is sandwiched 
between two connective tissue layers known as the periosteum on its outer surface and the 
endosteum on its inner layer. The cortical bone is itself made up of layers of smaller structures 
called osteons. These osteon are column like structures organized in the axial direction of the bone, 
and are made up of multiple layers of osteoblasts and osteocytes. These layers form around a 
central canal call the Haversian canal while other canals known as Volkmann’s canals connect 
osteons together in the perpendicular[4].  
Cancellous bone, also known as trabecular or spongy bone, is porous, making it much less 
dense than cortical bone. This lower density lends to its weaker mechanical properties[1]. 
Furthermore, its porosity also gives rise to greater surface area (ten times that of cortical bone), 
which is why it is where the majority of metabolic activity occurs within the skeletal system. 
Cancellous bone typically contains, within the porous structure, bone marrow and hematopoietic 
stem cells (which produce platelets, and red and white blood cells) [2], and is highly vascularized. 
Cancellous bone is organized through the formation of trabeculae, which are small rod or pillar 
like structures formed within the cancellous bone of long bones and oriented in the direction of 
mechanical loading[1]. 
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This brief overview of the organization and importance of bone and the skeletal system as 
a whole, should provide some understanding as to the complexity of the organ. This complexity 
gives rise to the myriad of issues involved when it comes to disease progression and the 
development of potential treatments. This will be important to keep in mind in the following 
sections, as we discuss the processes involved in bone remodeling and how disruption of these 
processes can lead to osteoporotic disease progression.  
1.2 Bone Remodeling and Osteoporotic Diseases 
In normal bone development, osteoclast-mediated bone resorption is balanced by 
osteoblast-mediated bone formation, resulting in no net loss of bone mass[5]. In severe 
osteoporotic diseases, an imbalance between bone resorption and bone growth occurs and can 
become dominant for severe diseases, such as, Paget’s disease, Osteogenesis Imperfecta (OI) and 
Legg Calve Perthes disease (LCPD). The dominant imbalance between resorption and growth seen 
in severe bone diseases can usually be attributed to relative over-activity of osteoclasts.  
Osteoclasts are phagocytic cells that share their origin with other dendritic cells and 
macrophages. They are differentiated from hematopoietic stem cells derived in bone marrow[6]. 
Mature osteoclasts are formed by activated precursor osteoclasts that fuse together and form 
multinucleated cells. These mature osteoclasts typically possess 5-8 nuclei, though extreme 
numbers have been reflected in diseases such as Paget’s[6]. Mature osteoclasts resorb bone by 
excreting acid as well as cathepsin K from a ruffled cellular membrane border that increases 
surface area to promote bone resorption. This dissolves the hydroxyapatite and fibrillar collagen 
that are taken up through the cell membrane and continues to be digested on the way to the 
secretory domain (Figure 1.2)[7]. Osteoclast mediated bone resorption is modulated by three major 
processes; recruitment, activity and life cycle of osteoclasts. It is here that bisphosphonates 
3 
 
(discussed in section 1.3) have been shown to act on osteoclasts through reduction of their viability, 
inhibition of their recruitment, reduction of their ability to bind to bone, and disruption of their 
morphology[5]. Furthermore, these processes are at least partially influenced by osteoblasts[5]. 
 Osteoblasts express proteins that have been shown to be a major factor in the remodeling process 
of bone. Osteoblasts express receptor activator of nuclear factor (NF)-κB ligand (RANKL) as well 
as osteoprotegerin (OPG) and these two along with RANK, RANKL’s receptor expressed on OC 
cells, play a critical role in the three processes of recruitment, binding, and life-cycle. RANKL 
binds with RANK expressed on the surface of pre-osteoclast cells to promote 
osteoclastogenesis[8]. OPG, expressed on the surface of osteoblasts, is a competitor protein to 
RANK that binds RANKL and helps to modulate the recruitment and differentiation process 
(Figure 1.3)[9]. Decreased expression of OPG or increased expression of RANKL could lead to 
increased osteoclastogenesis and thus potentially to osteoporosis. It is, therefore, important to 
consider the effects any potential treatment will have on this protein system. 
1.3 Bisphosphonates and Other Disease Treatments 
Bisphosphonates are most commonly used to treat general osteoporosis and in recent years, 
systemic delivery of bisphosphonates has also been considered for the treatment of severe 
osteoporotic diseases[10]. It is well known that amino-bisphosphonates (n-BP) have a strong 
inhibitory effect on osteoclasts, and are considered the strongest clinical inhibitors of bone 
resorption. Bisphosphonates were first used clinically to treat Paget’s disease[11].  
The bisphosphonates work by inhibiting enzymes in the mevalonate pathway of cholesterol 
synthesis[12]. This then leads to the reduction of levels of geranylgeranyl diphosphate. Since 
geranylgeranyl diphosphate is required for the prenylation of guanosine triphosphate (GTP)-
binding proteins that are necessary for osteoclast activity and survival [13, 14], reduction in GTP 
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decreases the levels of these binding proteins, thus compromising the viability of the cells. Overall, 
bisphosphonates have been shown to reduce osteoclast viability, inhibit osteoclast recruitment, 
inhibit osteoclasts-mediated resorption, reduce their ability to bind to bone, and disrupt 
morphology[5].   
There are two major classes of bisphosphonates: nitrogen-containing bisphosphonates 
(nBP) and non-nitrogen-containing bisphosphonates. The P-C-P structure of the bisphosphonate 
is strongly adherent to bone and depending on the specific structure of a given bisphosphonate, 
their deposition characteristics in bone may differ. For instance, alendronate has been shown to 
predominantly bind to bone resorption sites[15]. This strong affinity for bone adsorption leads to 
a natural targeting of osteoclasts as they are the only cells capable of resorbing bone[6]. 
Radiolabeled alendronate in in-vivo studies showed that a majority of the alendronate was uptaken 
by osteoclasts and not by other tissues in the body[12].  
Although bisphosphonates possess limited targeting capabilities, systematic delivery has 
drawbacks. In the case of LCPD, for example, osteonecrosis of the proximal epiphysis of the femur 
affects children between the ages of 2-14 years old and early stages of LCPD is marked by the lack 
of blood flow that leads to the osteonecrosis[16]. This lack of blood flow makes systemic delivery 
an inefficient treatment modality, as very little of the dosage will reach the target area. 
Additionally, the systemic delivery of bisphosphonates in the treatment of localized diseases, such 
as LCPD, can lead to undesired modulation of the bone remodeling process in other portions of 
the body. The most common example of this undesirable modulation is bisphosphonate-related 
osteonecrosis of the jaw[17]. This need for a localized delivery method and for a means to track 
treatments is a critical consideration in the development of future combination therapies and 
diagnostic aides. 
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1.4 Gold Nanoparticles 
The phagocytic nature of osteoclasts discussed previously can also be leveraged in the 
development of new treatment modalities, through the use of nanoparticles. Nanoparticles have 
many properties (electronic, catalytic, optical, and magnetic) that have made them an area of great 
interest for applications such as chemical synthesis, photonics, biological diagnostics and various 
medical therapies[18-21].  
Gold nanoparticles (GNP), for example, have been shown to be highly biocompatible, with 
low toxicity[22-24]. Optimization of shape, surface functionality, and size has been investigated 
for promoting optimal cellular uptake[25]. Gold nanoparticles have been investigated for use in 
drug delivery applications for cancer treatment with promising results[26]. Additionally, they have 
shown promising results as antimicrobial agents[22]. These features of GNP and the phagocytotic 
nature of osteoclast cells provide a potential route for the localized delivery. Further localization 
may also be achieved, either through direct delivery methods, such as intra-osseous injection 
directly into the avascular region as has been shown [27] in the case of LCPD, or through additional 
functionalization with a targeting agent[28]. 
Additionally, the properties of GNP make it ideal for image enhancement as well as other 
tracking and sensing techniques that would allow for the study of the disease and treatment 
progression. One such property is known as localized surface plasmon resonance (LSPR). LSPR 
is the harmonic oscillation of surface electrons when the electromagnetic frequency (light) matches 
that of the natural frequency of the electrons on the surface of the nanoparticles (Figure 1.4) [26, 
29, 30].  It is this feature that facilitates the use of gold nanoparticles in photo thermal ablation, 
radio-therapeutic dose enhancement, and molecular imaging among other applications.  In a recent 
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review by Curry et al. [31], gold nanoparticles have been shown as ideal contrast agents in 
computed tomography while mediating photothermal therapy. Bisphosphonate functionalized gold 
nanoparticles, in particular, have recently been shown  to be useful for contrast-enhanced X-ray 
detection of breast microcalcifications[32, 33].  
1.5 Research Focus: Bisphosphonate Functionalized Gold Nanoparticles as a Potential 
Treatment for Osteoporotic Disease 
The use of nanoparticles for disease treatment is an increasingly popular area of research. 
The potential for multi-functionality allows nanoparticles to be used as transport and delivery 
vehicles for drugs and as diagnostic aides, among other applications, to address the unmet needs 
of many such disease treatments. The overall goal of this doctoral research project is to study and 
discuss the application of gold nanoparticle systems surface functionalized with primary amine 
bisphosphonates, which is a classification of pharmaceuticals that is common in the treatment of 
osteoporosis. Functionalized nanoparticles allow for greater intracellular concentrations of 
pharmaceutical, while the properties of the gold nanoparticles may provide the ability to track the 
pharmaceutical and enhance imaging. Below, we broadly describe the organization of this 
dissertation to study the synthesis, characterization, and validation of bisphosphonate 
functionalized gold nanoparticles as a potential treatment and means of study for osteoporotic 
diseases.  
Chapter 2 discusses the method for synthesis and functionalization of the colloidal gold 
nanoparticles.  The research in this dissertation focuses on two different primary amine 
bisphosphonates, alendronate and pamidronate, and their self-assembly on the nanoparticle 
surface. The American Society of Clinical Oncology reports that the relative efficacy of 
alendronate to pamidronate is 10:1, and interest lies in whether this trend remains intact when 
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functionalized with GNP. It is important to note that efficacy is vaguely defined through multiple 
factors, including bone density, bone markers, and skeletal event free survival. These 
bisphosphonates were also chosen due to their common use as a benchmark for treatment in 
osteoporosis. The choice of these two n-BPs also allows for study of the effect that chemical 
structure might play on the formation of this nanoparticle system as they are very similar, but differ 
by one carbon in their carbon backbone (Figure 1.5). Chapter 2 also discusses characterization of 
the nanoparticles before and after functionalization through a suite of different techniques 
including UV-vis spectroscopy, dynamic light scattering (particle sizing), tunneling electron 
microscopy, and inductively coupled plasma mass spectrometry. These techniques provide insight 
into the particle size and distribution as well as providing an estimate of the surface bound 
bisphosphonate.  
Chapter 3 discusses in vitro studies that were used to investigate the effect of these 
bisphosphonate functionalized gold nanoparticles on cell viability and morphology. Two cell lines 
were used for these studies: Raw 264.7 murine pre-osteoclasts and 7F2 murine osteoblasts. The 
viability studies were done as mono cultures and co-cultures, as well as one study in the presence 
of bone slices and assessed through the use of a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) viability assay. The morphology was assessed through fluorescence 
microscopy in co-culture with the absence of bone. These studies provide insight into the effect of 
these nanoparticle systems across a range of concentrations. 
Chapter 4 describes the use of these nanoparticle systems in osteoclast and osteoblast in 
vitro cell cultures, looking deeper into their effects on cell performance, such as key protein 
expression and bone remodeling. Specifically we look into the effect of these nanoparticles on 
osteoblast expression of RANKL and alkaline phosphatase. As discussed previously RANKL is a 
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protein that plays a critical role in the bone remodeling process. Additionally, we look at how these 
nanoparticles impact alkaline phosphatase expression in osteoblasts, as a marker of osteoblastic 
differentiation and thus, an indicator of bone deposition[34]. Lastly, we discuss the effect of the 
nanoparticles on bone deposition and bone resorption through calcium deposition assays along 
with resorption assays and pit formation on bone slices. These final studies provide a more detailed 
look at the effect of bisphosphonate functionalized gold nanoparticles on cell behavior and bone 
remodeling. 
Finally, Chapter 5 provides an overall summary of the results of this study on the effects 
of this nanoparticle system as they pertain to these in vitro studies, and the discussion gives some 
insights on future prospects and recommendations. 
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Figure 1.1 Anatomy of bone. 
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Figure 1.2 Osteoclast development and bone resorption. 
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Figure 1.3 Osteoblast and osteoclast interaction. 
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Figure 1.4 Localized surface plasmon resonance. 
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Figure 1.5 Overview of the bisphosphonates used in this study. 
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CHAPTER 2:  
GOLD NANOPARTICLE SYNTHESIS AND CHARACTERIZATION1 
 In this chapter, a detailed description is given on synthesis and characterization of 
bisphosphonate functionalized gold nanoparticles. Our objective was to synthesize gold 
nanoparticles with controlled size that is suitable for cellular uptake and functionalize the surface 
using self-assembly by two different primary amine bisphosphonates. A host of characterization 
techniques were used to assess the gold nanoparticle system and clarify the surface-modification. 
Microscopy, spectroscopy, and scattering techniques were used to gain insight into the particle 
size distribution, shape, and to help confirm surface modification with bisphosphonates. 
Inductively coupled plasma mass spectrometry was used to ascertain the surface density of the 
bisphosphonates on the gold nanoparticle surface. 
2.1 Introduction 
 A means for localized delivery and in-vivo study of disease and treatment progression are 
desirable features of any treatment methodology. Nanoparticles are colloidal systems in the 
submicron size range that are stable when dispersed in solution[1]. Nanoparticles often have many 
properties (electronic, catalytic, optical, and magnetic) that have made them an area of great 
interest for applications such as catalysis and various medical therapies[2-5]. Gold nanoparticles, 
for example, have been shown to be highly biocompatible, with low toxicity, in many studies [6-
8]. Optimization of shape, surface functionality, and size has been investigated for promoting 
1 Part of this chapter was published in Conners, Christopher M., Bhethanabotla, Venkat R., and Gupta, Vinay K. 
(2015). "Concentration-dependent effects of alendronate and pamidronate functionalized gold nanoparticles on 
osteoclast and osteoblast viability." J Biomed Mater Res B. Permission is included in Appendix B. 
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optimal cellular uptake[9]. Gold nanoparticles have been investigated for use in drug delivery 
applications for cancer treatment with promising results[10]. Additionally, they have shown 
promising results as antimicrobial agents[6]. Gold nanoparticles possess an additional key feature 
that makes them interesting for medical imaging and sensing applications. This feature is the 
localized surface plasmon resonance (LSPR) that nanosized particles exhibit. LSPR is the 
harmonic oscillation of surface electrons when the electromagnetic frequency (light) matches that 
of the natural frequency of the electrons on the surface of the nanoparticles[10-12]. It is this feature 
that is exploited for use in photo thermal ablation, radio-therapeutic dose enhancement, and 
molecular imaging among many other applications.  
2.2 Materials and Methods 
2.2.1 Materials 
Alendronate sodium trihydrate and pamidronate disodium salt hydrate were obtained from 
Sigma-Aldrich, St Louis, USA. Snakeskin dialysis membranes with a 10k MWCO were obtained 
from SpectraPor. The optical absorption of the gold colloidal solutions were measured using a 
Jasco V-530 spectrophotometer (Jasco, MD, USA). Dynamic light scattering (DLS) was 
performed on a Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK) equipped with 
a red (633 nm) Helium-Neon laser. Transmission electron microscopy was done using a Morgagni 
268D TEM microscope (FEI, OR, USA).  TEM samples were prepared on Copper grid (200 mesh) 
with Formvar/Carbon film from Electron Microscopy Sciences. 
2.2.2 Gold Nanoparticle Synthesis and Functionalization 
The gold nanoparticles were synthesized via an adaptation of the well-established Frens 
method[13]. An aqueous solution of 110 ml of 1 mM HAuCl4 was reduced by 10 ml of 35 mM 
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citric acid while under refluxing conditions and continuous stirring.  The as-prepared gold 
nanoparticle solution was stored in an amber glass bottle at 4°C.   
 The citrate-stabilized gold nanoparticles were surface modified by taking advantage of 
what has been described as a coordination bond and partial electrostatic complex between primary 
amine groups and the surface of gold[14, 15].   The primary amine group in nBP such as 
alendronate and pamidronate can displace the citrate on the surface of the gold nanoparticles to 
form a thin organic overlayer.  Alendronate sodium trihydrate and pamidronate disodium salt 
hydrate were obtained (Sigma-Aldrich, St Louis, USA) and used to prepare aqueous solutions of 
1.1 mM concentration.  Typically, 1 mL of the as-prepared stock solution of gold nanoparticles 
was mixed with 0.8 mL of bisphosphonate stock solution and surface functionalization was 
allowed to occur over 24 h at room temperature. 
Excess bisphosphonate and citrate were removed by membrane dialysis using SpectraPor 
Snakeskin dialysis membrane with a 10k MWCO. Dialysis was performed over 24 hours, using 1 
L baths with bath changes at 2 and 10 hours. 
2.2.3 UV-vis Spectrophotometry 
The optical absorption of the gold colloidal solutions were measured using a Jasco V-530 
spectrophotometer (Jasco, MD, USA).  Before measurement, the sample of gold nanoparticle 
solution was typically diluted by a factor of 20.  The absorbance (A) at the plasmon absorption 
maximum is linearly proportional to number density of particles (Np) by the relation [16, 17]: 
 
' pA LNε=     (1) 
 
where L is the path length of the optical cell (1 cm) and ε’ is the molar extinction coefficient. 
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2.2.4 Dynamic Light Scattering 
Dynamic light scattering (DLS) was performed on a Zetasizer Nano ZS90 (Malvern 
Instruments, Worcestershire, UK) equipped with a red (633 nm) Helium-Neon laser.  The scattered 
light at 90° angle was recorded for a diluted colloidal solution (20X dilution) in a polystyrene 
cuvette at 20°C.  Two different samples and typically more than 10 measurement scans over a 
duration of 60 seconds for each sample were averaged.  The intensity size distribution from multi-
modal analysis of the correlation function (MNM algorithm) and the z-average diameter with 
polydispersity index as per the cumulants analysis was determined.  
2.2.5 Transmission Electron Microscopy 
For particle sizing, transmission electron microscopy was done using a Morgagni 268D 
TEM microscope (FEI, OR, USA).  Samples were prepared by drying a diluted drop of citrate–
stabilized gold nanoparticle solution on a copper grid (200 mesh) with Formvar/Carbon film.  The 
TEM image was analyzed using ImageJ software [18] (NIH) and manual selection of particles to 
determine a mean particle diameter.   
2.2.6 Inductively Coupled Plasma – Mass Spectroscopy 
Following literature reports [19, 20], Inductively Coupled Plasma Mass Spectrometry 
(ICP-MS) was used to characterize the bisphosphonate functionalized GNP in this study.  Samples 
and calibration standards were analyzed with an Agilent 7500cx ICP-MS in no-gas mode. 
Solutions were introduced into the ICP-MS with a MicroMist concentric nebulizer and a double-
pass (Scott-type) quartz spray chamber and Peltier cooled to 20°C.  Phosphorus was normalized 
to scandium, while gold was normalized to indium. Following the recommendation in Allabashi 
et al. [19], acidification with 1% HCl (v/v) was used.  Samples were quantified using an external 
calibration line composed of a blank and 5 standards in 1% HCl. The integration time was set at 
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0.50 seconds for phosphorous and 0.10 seconds for Au, and the number of repetitions was set to 
five. Each sample was run in triplicate. HCl blank solution (1%) was analyzed prior to each 
standard and sample to monitor memory effects, although no correction was required.  To estimate 
bisphosphonate molecules per unit area of spherical nanoparticles the mass ratio (Rm) of 
phosphorous to gold was determined for the functionalized gold nanoparticles.  For particles with 
a diameter D, the following relation was used for the surface density (σ) of alendronate or 
pamidronate: 
 
2 6
m
Av Au
p
R DN
m
σ ρ=    (2) 
 
where mP is the atomic weight of phosphorous, NAv is the Avogadro’s number, ρAu is the density 
of bulk gold and the factor 2 accounts for two phosphorous atoms per bisphosphonate molecule. 
2.2.7 Statistical Analysis 
Statistical results are expressed as means +/- SD. Comparisons between data were made 
with the use of student’s t-test where significance was determined at p ≤ 0.05. 
2.3 Results and Discussion 
Characterization of nanoparticle size typically requires more than one technique to obtain 
an adequate picture of the size distribution[21].  Figure 2.1 shows a representative TEM image of 
the gold nanoparticles and the size distribution obtained from TEM. Figure 2.2 provides the 
intensity size distribution from DLS.  The average size of the nanoparticles is approximately 15±3 
nm (n=47) from TEM.  The DLS results show a size distribution with a single peak that is centered 
at 23±8 nm; the cumulants analysis gives z-average hydrodynamic diameter as 18 nm 
(polydispersity index 0.26).   
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While electron microscopy reflects the primary size of the particle, the statistical 
representation of the distribution is poor due to small numbers and issues also exist from 
aggregation or drying during sample preparation[21].  DLS on the other hand rapidly provides an 
ensemble average with good statistical representation but provides hydrodynamic diameter of 
particles and the intensity of scattered light is sensitive to the presence of small quantities of large 
particles or clusters of smaller particles, which can skew the size distribution.    The results from 
TEM and DLS in Figures 2.1 and 2.2 are in agreement with each other and suggest that the 
nanoparticles population is 10-30 nanometers in diameter.  The results in Figures 2.1 and 2.2 are 
also consistent with the preparation method used here.  Direct reduction of gold salt in the presence 
of a stabilizer-reducer agent i.e. the well-established Frens method has been shown [13] to work 
well in preparing particles with diameters up to 30 nm.  The size range in Figure 2.1 is also 
appropriate for cellular uptake through endocytosis[22]. Additionally, it is well accepted that 
nanoparticle systems for in vivo use should remain below 100 nm in diameter to be most effective 
in systemic delivery[9, 23]. 
Figure 2.3 shows the optical absorption characteristics of the gold nanoparticles systems. 
The as-prepared GNP system has a plasmon absorbance maximum at a wavelength of 521 nm and 
a plasmon bandwidth of approximately 60 nm.  The absorbance peak near 521 nm is typical of 
gold nanoparticles with average diameter in range of 15-25 nm[16, 24, 25]. This also leads to the 
well-known red wine colored appearance of colloidal gold solutions of this size (Figure 2.4). The 
plasmon bandwidth of 60 nm is also consistent with absence of significant numbers of small (<10 
nm) or large (> 50 nm) sized nanoparticles (see Link and El-Sayed [16]), which is in agreement 
with the DLS analysis shown in Figure 2.2.   
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Results in Figure 2.3 reveal that the pamidronate and alendronate functionalized gold 
nanoparticles exhibit maxima at 522 nm and 523 nm, respectively.  No significant broadening of 
the absorption peak post-functionalization is observed.   The slight red-shift in the case of 
alendronate and pamidronate functionalized gold nanoparticle is congruent with the molecular size 
of the bisphosphonates and expectation of a thin organic layer [26] on the surface of gold 
nanoparticles and is also in agreement with past studies[27].   
 Using the optical absorbance for the gold nanoparticles at the plasmon maxima and the 
molar extinction coefficient, Np can be estimated using equation 1.  However, the effect of 
nanoparticle size on ε’ is an important consideration in a polydisperse distribution. Link and El-
Sayed [16] have shown that the molar extinction coefficient (ε’) of the spherical gold nanoparticles 
increases with increase in diameter of the nanoparticles.  From their report, ε’ can change from 
~8x107 M-1cm-1 for a diameter of 9 nm to ~1.3x109 M-1cm-1 for a diameter of 22 nm or  ~2x1010 
M-1cm-1 for a diameter of 48 nm.  Here, a diameter of 15 nm, an interpolated ε’, and the absorbance 
for as-prepared gold nanoparticle solutions gives the estimated Np as ~5x1012 particles/mL.   Using 
the quantity of gold salt used in the nanoparticle synthesis and assuming complete quantitative 
reduction with no losses also yields a value for Np of ~5x1012 particles/mL, which agrees quite 
well with the estimate from optical absorption. 
Allabashi et al. [19] have shown recently that ICP-MS can be used for gold nanoparticle 
characterization without a digestion step.  Hinterworth et al. [20] have used the approach to 
demonstrate quantification of ligand density for several thiol ligands on various sized gold 
nanoparticles.  Using similar procedures, the bisphosphonate functionalized nanoparticles (GP and 
GA) were characterized by ICP-MS.  Measurements show a phosphorous to gold mass ratio of 
Rm= 0.0055 for GA and Rm=0.0014 for GP.  ICP-MS quantification of the gold content in a sample 
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of gold nanoparticles alone yields a value of ~194 ppm that on combination with the TEM results 
gives an estimated nanoparticle concentration Np of ~6x1012 particles/mL, which is consistent with 
the other estimates above. 
The mass spectrometry results support the immobilization of nitrogen containing 
bisphosphonates (nBP) on the surface of the gold nanoparticles.  Additionally, by combining 
equation 2 and the average diameter of 15 nm, ICP-MS measurements of the bisphosphonate 
functionalized nanoparticles yield a surface density (σ) of approximately 0.65 molecules per nm2 
(approximately 154 Å2/molecule) for GP and approximately 2.6 molecules per nm2 (approximately 
39 Å2/molecule) for GA.  The values for σ indicate a much less dense packing density than the 4.6 
molecules per nm2 that is well-known for a strongly chemisorbed and well-ordered monolayer of 
long chain n-alkanethiol molecules on planar gold surfaces with Au(111) crystallography[28, 29].  
The nature of the bond [14, 15] between amines and the gold surface as well as the large 
bisphosphonate head group possibly contribute to the lower packing density for pamidronate and 
alendronate.   
It is important to note that the above surface density values for GA and GP are estimates 
given the polydispersity in size of the nanoparticles as well as factors such as non-spherical shape 
of particles that impact other binding sites (edges and corners).  An investigation directed on the 
self-assembly of nBPs with controlled synthesis of nanoparticles with several sizes is necessary 
for a well-defined value.  Past literature on thiol-gold self-assembled monolayers shows that 
shorter ligand chain lengths lead to lower surface density [30, 31] and the difference between 
values for GP and GA is plausibly due to a similar effect from the shorter chain length of 
pamidronate.  In this context, a comparative surface study of gold nanoparticle functionalization 
with pamidronate, alendronate, and neridronate can be useful. 
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Figure 2.1 Size distribution of gold nanoparticles obtained from TEM. Inset shows a representative 
TEM image with a 100 nm scale bar. 
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Figure 2.2 Intensity size distribution from dynamic light scattering analysis from the gold 
nanoparticle solution. 
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Figure 2.3 UV-vis spectra of the gold nanoparticles before and after conjugation with 
bisphosphonates.  The spectra are marked as follows:  for gold nanoparticles alone;  for gold 
nanoparticles conjugated with pamidronate;  for gold nanoparticles conjugated with alendronate.  
Sparse markers have been used with one marker for every 15 data points. 
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Figure 2.4 Image of the as-prepared gold nanoparticle stock solution. 
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CHAPTER 3:  
CELL VIABILITY AND MORPHOLOGY1 
In this chapter, a detailed description is given on effects of bisphosphonate functionalized 
gold nanoparticles on the viability and morphology of osteoclast and osteoblast cells in vitro. The 
objective was to analyze the effect that modified nanoparticles had on cell viability and 
morphology under different circumstances. The circumstances included mono-cultures of 
osteoclasts and of osteoblasts as well as more physiologically relevant co-cultures that relied on 
the RANKL expression of osteoblasts to differentiate the Raw 264.7 pre-osteoclast cells.  
Colorimetric assays were used to quantify cell viability and fluorescence microscopy was used to 
look at morphological changes in the cells’ structures. 
3.1 Introduction 
 
 It is well established that aminobisphosphonates (n-BP) have a strong inhibitory effect on 
osteoclasts, and are considered the strongest clinical inhibitors of bone resorption. 
Bisphosphonates have been shown to reduce osteoclast viability, inhibit osteoclast recruitment, 
inhibit osteoclasts-mediated resorption, reduce their ability to bind to bone, and disrupt 
morphology[1]. Bisphosphonates were first used clinically to treat Paget’s disease[2]. Their 
inhibitory effect works by inhibiting enzymes in the mevalonate pathway of cholesterol 
synthesis[3]. This then leads to the reduction of levels of geranylgeranyl diphosphate. Since 
geranylgeranyl diphosphate is required for the prenylation of guanosine triphosphate (GTP)-
1 Part of this chapter was published in Conners, Christopher M., Bhethanabotla, Venkat R., and Gupta, Vinay K. 
(2015). "Concentration-dependent effects of alendronate and pamidronate functionalized gold nanoparticles on 
osteoclast and osteoblast viability." J Biomed Mater Res B. Permission is included in Appendix B. 
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binding proteins that are necessary for osteoclast activity and survival [4, 5], this reduces the levels 
of these binding proteins and compromises the viability of the cells. Finally, mature osteoclasts 
resorb bone by excreting acid as well as cathepsin K from a ruffled cellular membrane border that 
increases surface area to promote bone resorption. This dissolves the hydroxyapatite and fibrillar 
collagen that are taken up through the cell membrane and continues to be digested on the way to 
the secretory domain [6]. Any disruption to this the cell morphology may lead to an inability to 
perform its normal functions. 
 Additionally, there have been studies that assert the positive effects of bisphosphonates on 
osteoblast proliferation and bone nodule formation. Im et al. [7] showed that both alendronate and 
risedronate increased cell count of both primary human trabecular bone and MG-63 osteoblast-
like cells in vitro, with a maxima at about 10-8 M. Reinholz et al. [8] had the opposite effect with 
starting concentrations of about 4x10-5 M. Results of a study by Schindeler et al. [9] show that 
bound bisphosphonates have nearly no comparable effect on osteoblasts compared to osteoclasts 
when they are cultured separately on phosphate coated quartz disks that were pretreated with 
zoledronic acid. Their results showed that although osteoclasts were negatively influenced by this 
substrate, osteoblasts were largely unaffected. Similar results were shown by Panzavolta et al.[10]. 
It has also been reported that at sufficiently low concentrations, bisphosphonates prevent apoptosis 
by etoposide and corticosteroids in osteoblasts and osteocytes. This is done through connexin 43 
channels and extracellular signal-regulated kinase (ERK) phosphorylation[11, 12]. 
 However, there are numerous studies that present results of the negative effect of 
bisphosphonates on osteoblast viability. A study by Orriss et al. [13] showed that zoledronate, 
would reduce the number for osteoblast cells at concentrations equal to or greater than 100 nM. 
Similar results were shown for pamidronate and clodronate, only at substantially higher 
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concentrations of greater than or equal to 1 and 10 µM for pamidronate and clodronate 
respectively. However, they did see generally positive effects on proliferation for concentrations 
in the 1 nM to 1 µM range, with the exception of zoledronate. Idris et al. [14] show either no effect 
or a slight positive effect on proliferation in the range of 100 nM or 1 µM (the lowest dose results 
shown) when rabbit and mice osteoblasts were treated with pamidronate and alendronate in vitro.  
 The above discussion of past studies makes it apparent that though the conclusions of these 
studies seem to differ, they also differ in the parameters of the studies. It is, therefore, important 
whenever developing a new treatment to carefully consider all of these variables. 
3.2 Materials and Methods 
3.2.1 Materials 
Alendronate sodium trihydrate and pamidronate disodium salt hydrate were obtained from 
Sigma-Aldrich, St Louis, USA. Gold nanoparticle solutions were prepared as discussed in Chapter 
2. Raw 264.7 murine pre-osteoclast cells and 7F2 murine osteoblast cells were obtained from 
ATCC. Dulbecco's Modified Eagle's Medium (DMEM) (Cellgro, Mediatech, VA, USA) was 
supplemented with 10% (vol/vol) fetal bovine serum (Sigma) and 1% (vol/vol) antibiotic–
antimycotic (Sigma). Viability was assessed using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Invitrogen) colorimetric assay. Absorbance for MTT assay was 
read on a Synergy HT Microplate Reader from BioTek (Winooski, VT, USA). The rabbit anti-
actin primary antibody goat anti-rabbit IgG and DAPI were all obtained through Sigma-Aldrich, 
St Louis, USA. Fluorescence microscopy images were captured using an EVOS FL Cell Imaging 
System from Invitrogen. 
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3.2.2 RANKL Differentiation of Raw 264.7 Pre-Osteoclast Cell Line 
Murine pre-osteoclast cells (RAW 264.7) were recovered from cryogenic storage in 1× 
DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine serum 
(Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% relative 
humidity. At approximately 80% confluence, the Raw 264.7 cells were cultured in media 
supplemented with 50 ng/ml of recombinant mouse receptor activator of NF-κB ligand, or 
RANKL, (R&D Systems, MN, USA) and allowed to incubate for eight days to encourage 
differentiation into mature osteoclasts. This protocol was applied in all studies where osteoclast 
cells were used unless otherwise noted.  
3.2.3 Osteoclast Viability Study 
 RANKL-differentiated Raw 264.7 cells were seeded at a density of 4×103 cells/well in a 
96-well plate. After allowing the cells to attach to the culture dish for 24 hours, the cells were 
treated with the different variables as described. 
A 72 h study was conducted with six groups, each done in triplicate, and designated as 
follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells treated with 
pamidronate functionalized GNP (GP), cells treated with alendronate functionalized GNP (GA), 
cells treated with free pamidronate (P), and cells treated with free alendronate (A).  Each treatment 
was mixed with fresh medium before being added to the cells.  The untreated cells (C) served as 
the control.  For the free bisphosphonates, osteoclasts were treated with 1 to 5 μM of 
bisphosphonates. These treatment concentrations are comparable to concentrations (1 nM -10 µM) 
that have been used in other in vitro studies[15, 16].  In the case of samples treated with gold 
nanoparticle systems, treatment with 10-50 μL of nanoparticle solution was used. In each case, the 
50 μL volume i.e. the highest treatment concentration, corresponded to ~4x107 nanoparticles/cell.   
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See Figure 3.1 for a schematic of the experimental design. A separate control was used for each 
triplicate group so that the volume ratio of treatment to medium was maintained. 
At the end of the 72 hour treatment period, the spent culture media was removed and 100 
µl of fresh culture media supplemented with MTT powder at a concentration of 5 mg/ml, was 
added to all wells.  The cells were then incubated at the previously described conditions for 4 
hours. The purple formazan crystals were then dissolved with 100 µl of DMSO after removing the 
media.  After 30 minutes on a rocker, absorbance was read at 540 nm with a reference filter at 630 
nm[17].  A standard curve was produced through a similar procedure using untreated cells for each 
cell line and all results were found to be within the range and linear region of the curve (Figure 
3.3). 
A separate study was conducted over 24 hours in order to assess the mechanism by which 
the nanoparticles were internalized by the cells. This required a toxicity study to determine a safe 
concentration of amiloride. Cells were treated with 10 serial dilutions of amiloride, with a 
maximum concentration of 40 µg/mL over a 24 hour period. This time period was chosen because 
of the relatively high toxicity of amiloride, in an attempt to minimize its effect.  Following this 
study, a similar viability study to the one described previously, was done using two different 
amiloride treatments. The cells were pretreated for 1 hour with 0 µg/mL, 1.25 µg/mL or 10 µg/mL 
of amiloride and then the same treatments noted above were added without the removal of the 
amiloride. At the end of the 24 hour period, the viability was assessed through MTT.   
 3.2.4 Osteoblast Viability Study 
Murine osteoblast cells (7F2) were recovered from cryogenic storage in 1× DMEM 
(Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine serum (Sigma) and 
1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% relative humidity. Cell 
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viability was assessed 72 hours after treatment with a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Invitrogen) colorimetric assay. Subsequently, the osteoblasts were 
seeded at a density of 2×103 cells/well in a 96-well plate. The difference in seed count from the 
previously described osteoclasts viability study was due to size difference of the cells and concern 
about overcrowding. After allowing the cells to attach to the culture dish for 24 hours, the cells 
were treated with different variables as described.  
A 72 h study was conducted with six groups, each done in triplicate, and designated as 
follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells treated with 
pamidronate functionalized GNP (GP), cells treated with alendronate functionalized GNP (GA), 
cells treated with free pamidronate (P), and cells treated with free alendronate (A).  Each treatment 
was mixed with fresh medium before being added to the cells.  The untreated cells (C) served as 
the control.  For the free bisphosphonates, osteoblasts were treated with 0.5 to 2.5 μM of 
bisphosphonates as one-half the seeding density was used compared to the previously discussed 
osteoclast study.  These treatment concentrations are comparable to concentrations (1 nM -10 µM) 
that have been used in other in vitro studies[15, 16].  In the case of samples treated with gold 
nanoparticle systems, treatment with 10-50 μL of nanoparticle solution was used. In each case, the 
50 μL volume i.e. the highest treatment concentration, corresponded to ~4x107 nanoparticles/cell.  
See Figure 3.5 for a schematic of the experimental design. A separate control was used for each 
triplicate group so that the volume ratio of treatment to medium was maintained. 
At the end of the 72 hour treatment period, the spent culture media was removed and 100 
µl of fresh culture media supplemented with MTT powder at a concentration of 5 mg/ml, was 
added to all wells.  The cells were then incubated at the previously described conditions for 2. The 
purple formazan crystals were then dissolved with 100 µl of DMSO after removing the media.  
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After 30 minutes on a rocker, absorbance was read at 540 nm with a reference filter at 630 nm[17].  
A standard curve was produced through a similar procedure using untreated cells for each cell line 
and all results were found to be within the range and linear region of the curve (Figure 3.7). 
3.2.5 Co-Cultured Viability Study 
Murine pre-osteoclast cells (RAW 264.7) and murine osteoblast cells (7F2) were recovered 
in 1× DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine 
serum (Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% 
relative humidity. Subsequently, the undifferentiated Raw 264.7 cells and the osteoblasts were 
seeded together (co-culture) at a density of 4×103 cells/well and 2×103 cells/well respectively in 
96-well plates. Note that the Raw 264.7 cells were not differentiated with RANKL prior to seeding 
as the 7F2 osteoblast cells express RANKL and this co-culture was intended to reflect 
physiologically relevant conditions. These seeding densities allow for comparable particle/cell 
concentrations as seen in the mono-culture experiments. After allowing the cells to attach to the 
culture dish for 24 hours, the cells were treated with different variables as described below. 
A 72 h study was conducted with six groups, each done in triplicate, and designated as 
follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells treated with 
pamidronate functionalized GNP (GP), cells treated with alendronate functionalized GNP (GA), 
cells treated with free pamidronate (P), and cells treated with free alendronate (A).  Each treatment 
was mixed with fresh medium before being added to the cells.  The untreated cells (C) served as 
the control.  For the free bisphosphonates, the cells were treated with 1 to 5 μM of bisphosphonates. 
These treatment concentrations are comparable to concentrations (1 nM -10 µM) that have been 
used in other in vitro studies[15, 16].  In the case of samples treated with gold nanoparticle systems, 
treatment with 10-50 µL of nanoparticle solution was used. In each case, the 50 µL volume i.e. the 
38 
 
highest treatment concentration, corresponded to ~2.7x107 nanoparticles/cell.   A separate control 
was used for each triplicate group so that the volume ratio of treatment to medium was maintained. 
At the end of the 72 hour treatment period, the spent culture media was removed and 100 
µl of fresh culture media supplemented with MTT powder at a concentration of 5 mg/ml, was 
added to all wells.  The cells were then incubated at the previously described conditions for 2. The 
purple formazan crystals were then dissolved with 100 µl of DMSO after removing the media.  
After 30 minutes on a rocker, absorbance was read at 540 nm with a reference filter at 630 nm[17].  
See Figure 3.8 for a schematic of the experimental design. A standard curve was produced through 
a similar procedure using untreated cells for each cell line and all results were found to be within 
the range and linear region of the curve (Figure 3.10). 
3.2.6 Morphology via Fluorescence Microscopy 
Murine pre-osteoclast cells (RAW 264.7) and murine osteoblast cells (7F2) were recovered 
in 1× DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine 
serum (Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% 
relative humidity. Subsequently, the undifferentiated Raw 264.7 cells and the osteoblasts were 
seeded together (co-culture) at a density of 4×103 cells/well and 2×103 cells/well respectively in 
96-well plates. Note that the Raw 264.7 cells were not differentiated with RANKL prior to seeding 
as the 7F2 osteoblast cells express RANKL and this co-culture was intended to reflect 
physiologically relevant conditions. These seeding densities allow for comparable particle/cell 
concentrations as seen in the mono-culture experiments. After allowing the cells to attach to the 
culture dish for 24 hours, the cells were treated with different variables as described below. 
Fluorescence imaging was done 72 h after treatment with six groups designated as follows: 
untreated cells (C), cells treated with non-functionalized GNP (G), cells treated with pamidronate 
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functionalized GNP (GP), cells treated with alendronate functionalized GNP (GA), cells treated 
with free pamidronate (P), and cells treated with free alendronate (A).  Each treatment was mixed 
with fresh medium before being added to the cells.  The untreated cells (C) served as the control.  
For the free bisphosphonates, the cells were treated with 3 μM of bisphosphonates. These treatment 
concentrations are comparable to concentrations (1 nM -10 µM) that have been used in other in 
vitro studies[15, 16].  In the case of samples treated with gold nanoparticle systems, treatment with 
30 µL of nanoparticle solution was used corresponded to ~1.6x107 nanoparticles/cell.    
At the end of the 72 hour treatment period, the spent culture media was removed and the 
cells were rinsed with 1x PBS. The cells were then fixed with 4% p-Formaldehyde at room 
temperature for 10 minutes. After rinsing with 1x PBS, a permeabilization step was performed by 
treating the cells with 0.1% Triton X100 in 1x PBS for 5 minutes. The rabbit anti-actin (1:1000 in 
3% BSA, Sigma) primary antibody was then added to each well and incubated for 1 hour at room 
temperature. After rinsing with 0.1% Triton X100 in 1x PBS the goat anti-rabbit IgG (1:500, 3% 
BSA, Sigma) secondary antibody was added and allowed to incubate at room temperature for 1 
hour. After rinsing again with 0.1% Triton X100 in 1x PBS, DAPI nuclear stain (300 nM in 0.1% 
Triton X100, Sigma) was added to each well for 10 minutes at room temperature before rinsing 
with 1x PBS. The samples were then imaged using an EVOS FL Cell Imaging System from 
Invitrogen (DAPI excites at 357 nm with emissions at 447 nm and FITC excites at 470 nm with 
emissions at 525 nm). 
3.2.7 Statistical Analysis 
Statistical results are expressed as means +/- SD. Comparisons between data were made 
with the use of student’s t-test where significance was determined at p ≤ 0.05. 
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3.3 Results and Discussion 
3.3.1 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Osteoclast 
Viability 
Figure 3.2 compares results from treatment of osteoclast (Raw 264.7 cell line, 4000 
cell/well) samples with increasing concentration of bisphosphonates. In Figure 3.2A, treatment 
with free bisphosphonates shows a lack of significant differences compared to the controls over 
the entire concentration range.  In Figures 3.2B and 3.2C, the gold nanoparticles alone (sample G) 
has no effect on osteoclast viability in all but the highest treatment concentration where a 
statistically significant decrease in osteoclast cell viability compared to the controls is observed. 
Most importantly, Figures 3.2B and 3.2C show that when the osteoclasts are treated with 
pamidronate and alendronate conjugated to gold nanoparticles (GP and GA, respectively), there is 
a significant decrease in cell viability above 40% treatment, which corresponds to ~6x1010 
functionalized particles or ~0.3 µM for pamidronate and ~1 µM for alendronate using the estimate 
of surface density (σ) noted in Chapter 2.  
The lack of significant decrease in OC viability upon treatments by pamidronate or 
alendronate in their free form (Figure 3.2A) agree with the report by Martins et al. [15] wherein 
differentiated Raw 264.7 cells showed a decrease in cell viability only when treated with a 
concentration of 10 µM or larger of alendronate.  Additionally, Tsubaki et al. [16] reported a 
decrease in cell viability at 5 µM of alendronate and above, though they used the C7 osteoclast 
cell line, which suggests that the threshold is sensitive to the cell line.  The lack of significant 
decrease in OC viability upon treatment with gold nanoparticles alone indicates that GNPs likely 
have no significant effects on the viability of these cell lines when they are not conjugated with 
BPs and this result is in agreement with what is typically reported in literature about the low 
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toxicity of GNPs on mammalian cells[18-20]. The one exception to the above is the decrease in 
viability for osteoclasts at the 100% treatment in Figure 3.2B and 3.2C.  This likely represents a 
slight cytotoxic effect of the gold nanoparticles on this particular cell line at the highest 
nanoparticle per cell concentration (approximately 4x107 nanoparticles/cell). 
A primary goal of this study was to determine the effect of delivering bisphosphonate 
bound to gold nanoparticles rather than in its free form. It is well known that amine-containing 
bisphosphonates have a strong inhibitory effect on osteoclasts, and are considered the strongest 
clinical inhibitors of bone resorption. Bisphosphonates were first used clinically to treat Paget’s 
disease [2] and their inhibitory effect works by inhibiting enzymes in the mevalonate pathway of 
cholesterol synthesis[3]. This then leads to the reduction of levels of geranylgeranyl diphosphate. 
Since geranylgeranyl diphosphate is required for the prenylation of guanosine triphosphate (GTP)-
binding proteins, which are necessary for osteoclast activity and survival [4, 5], this reduces the 
levels of these binding proteins, thus compromising the viability of the cells.  The comparison in 
Figure 3.2 shows that attaching the bisphosphonates to the surface of the nanoparticles leads to 
increased apoptotic effects of the bisphosphonates on the OC cells. This can likely be attributed to 
the fact that OC cells are predominantly endocytotic in nature and have been shown to readily 
internalize GNP through endocytosis[21, 22]. With OC cells normally internalizing by means of 
endocytosis, not much free BP would normally be taken up, as there is nothing about the small 
molecule that should activate an endocytosis or micropinocytosis pathway. This leaves only 
diffusive and membrane protein channel mediated uptake of the free drug. However, GNP is 
readily internalized and with each particle approximately 102-103 molecules of surface attached 
BP are carried into the cell. The greater intercellular concentration of the bisphosphonates, is, 
plausibly, the reason for the lower cell viability. Similar phenomenon has also been noted in the 
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literature by Champion et al. in their study of detailing increased enzymatic activity upon higher 
particle uptake in cells[23, 24]. A study was attempted in the interest of investigating this 
hypothesis.  
Since these gold nanoparticle systems do not possess any signaling moieties that would 
trigger specific uptake into the cell, the likely mode of uptake is macropinocytosis[25]. 
Macropinocytosis is a regulated form of endocytosis that mediates the non-selective uptake of 
various extracellular components and it is a highly active feature of macrophage related cell types 
[25] like osteoclasts. Amiloride is a well-known inhibitor of the macropinocytic pathway  and acts 
by inhibiting the Na+/H+ exchanger pump in the plasma membrane[26, 27]. The intent was to 
block macropinocytosis via treatment with amiloride, and then compare viability results of 
amiloride blocked and unblocked cells when treated with functionalized gold nanoparticles. By 
blocking the likely pathway for uptake of these gold nanoparticles, we should see a decreased 
effect on cell viability. First, it was necessary to determine a safe concentration of amiloride for 
this cell line, as it has been shown to be relatively toxic. Figure 3.4 shows the results of the toxicity 
study. There appears to be a plateau (at ~10 µg/mL) in the viability as the concentration of 
amiloride decreases. Note that with the exceptions of the 5, 2.5, and 1.25 µg/mL treatments, all 
treatments showed significant decreases in viability, even at lower concentrations. We chose to 
move forward with two different amiloride concentrations, 10 and 1.25 µg/mL. Unfortunately, the 
study was inconclusive.  Every attempt showed either no decrease in viability that should coincide 
with previous studies, or all amiloride treatments further decreased cell viability beyond that of 
the normal treatments. Further study into the internalization mechanism would be useful in further 
development of nanoparticle based treatments. 
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3.3.2 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Osteoblast 
Viability 
Figure 3.6 compares samples of osteoblast (7F2 cell line, 2000 cells/well) treated with 
similar increasing concentration. In case of treatment with free bisphosphonates, Figure 3.6A 
shows no effect of treatment on osteoblasts at all but the highest concentration of free alendronate.  
Figures 3.6B and 3.6C show that gold nanoparticles alone (G) have no effect on osteoblast viability 
at all treatments. In case of treatments with functionalized nanoparticles, only at sufficiently high 
variable concentration there are significant differences compared to the controls.  Figure 3.6B 
shows osteoblast viability is significantly decreased compared to the controls beyond 60% 
treatment for GP, which corresponds to ~5x1010 functionalized particles or ~0.2 µM for 
pamidronate using the estimate of surface density (σ). Figure 3.6C shows lack of significant 
decrease in osteoblast viability at all but the highest variable concentration of 100% for GA, which 
corresponds to approximately 0.8x1011 functionalized particles or ~1.5 µM for alendronate using 
the estimate of surface density (σ). 
It is also necessary to elucidate the effects of GP and GA on OB viability compared to the 
free forms of the bisphosphonates. The validity of this mode of treatment hinges on the ability to 
shift the balance from bone resorption in the direction of bone formation. In order to leverage 
viability as a means of shifting the balance, it is necessary to decrease the viability of the OC cells 
while having no significant effect on OB cell viability. As can be seen in Figure 3.6, there is no 
decrease in OB viability with increasing concentration of free bisphosphonates until the 2.5 µM 
free alendronate treatment.  In case of the functionalized nanoparticles, a significant decrease 
compared to controls is observed when treatment concentration reaches ~0.5x1011 particles for GP 
(~0.2 µM pamidronate) and ~0.8x1011 particles for GA (~1.5 µM alendronate).  These results are 
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in general agreement with what is reported in the literature, where BP, at sufficiently low 
concentrations, have been shown to prevent apoptosis by etoposide and corticosteroids in 
osteoblasts and osteocytes[9, 10]. These viability results provide insight into the optimization of 
potential treatment concentrations. 
3.3.3 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Co-Culture 
Viability 
Figure 3.9 compares results from treatment of osteoclast (Raw 264.7 cell line, 4000 
cell/well) and osteoblast (7F2 cell line, 2000 cells/well) co-culture samples with increasing 
concentration of bisphosphonates. In Figure 3.9A, treatment with free bisphosphonates shows a 
lack of significant differences compared to the controls over the entire concentration range with 
the one exception of the 60% (3 µM) pamidronate.  In Figures 3.9B and 3.9C, the gold 
nanoparticles alone (sample G) shows a statistically significant decrease in cell viability for the 
40% and 60% treatments compared to the controls, which corresponds to ~6x1010 and ~1x1011 
particles respectively. However, Figures 3.9B and 3.9C also shows that when the cells are treated 
with pamidronate and alendronate conjugated to gold nanoparticles (GP and GA, respectively), 
there is a significant decrease, compared to controls, in cell viability starting at 40% treatment and 
increasing with concentration. This corresponds to a concentration range of ~6x1010 to ~1.6 x1011 
functionalized particles or ~0.3 µM to ~0.8 µM for pamidronate and ~0.6 µM to ~1.6 µM for 
alendronate. Most importantly, these same treatments are all statistically significant decreases 
when compared to gold nanoparticles alone in all but the highest concentration of pamidronate 
functionalized gold nanoparticles. The estimate of surface density (σ) noted in Chapter 2 was again 
used to establish these values. 
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As discussed previously, OC and OB cells work closely together to keep the bone 
remodeling process in check. Osteoclast formation through differentiation into multinucleated 
mature osteoclasts are formed by fusion of circulating precursor hematopoietic cells [28] and 
require cell-to-cell interaction between said precursor’s and osteoblasts[29].  This interplay 
between these cells is extremely important in maintaining balance, so it is important to consider 
the effects of GP and GA versus the free bisphosphonates on a more physiologically relevant co-
culture. As can be seen in Figure 3.9A, there is no decrease in overall viability with increasing 
concentration of free bisphosphonates with the one exception of 3 µM free pamidronate treatment.  
Figure 3.9B and 3.9C show an apparent toxicity to GNP alone with a threshold at ~6x1010 particles. 
Although the approximate nanoparticle per cell concentration remained similar between this co-
culture study and the previously discussed mono-culture studies, the total nanoparticle and surface 
bound bisphosphonate concentrations were twice the total concentration in the osteoblast viability 
study. This greater available quantity of GNP may have led to the apparent toxicity, as there is no 
way to separate the viability data of the two cell lines in this co-culture study. Although GNPs 
have been reported as having low cytotoxicity to various cell lines [19, 30], the concentration of 
GNP used in these studies are orders of magnitude greater and may be encroaching on the toxicity 
limit of these cells. Furthermore, as a limit to in vitro studies, we cannot reproduce the ability of 
an in vivo system to clear nanoparticles from the body through the renal system for example[31]. 
Repeated dosing is difficult in vitro as the gold nanoparticle concentrations would continue to rise 
with every does and compound the cytotoxic effects. With an in vivo system’s ability to clear the 
nanoparticles over time, a dosing regimen is more viable. In the case of the functionalized 
nanoparticles, a significant decrease compared to controls and GNP alone is observed when the 
treatment concentration reaches ~6x1010 functionalized particles and decreases further with 
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increasing treatment concentration to ~1.6 x1011 functionalized particles. These values correspond 
to ~0.3 µM to ~0.8 µM for pamidronate and ~0.6 µM to ~1.6 µM for alendronate bound to the 
surface based on the estimate of surface density (σ) discussed in chapter 2. These results are in line 
with the previously discussed mono-culture studies, where we see an increased effect on cell 
viability at significantly lower concentrations of bisphosphonates. This is likely in part due to the 
fact discussed previously, that OC cells are predominantly endocytotic in nature and have been 
shown to readily internalize GNP through endocytosis[21, 22]. These viability results bring to light 
a number of potential considerations into the optimization of potential treatments, such as dosing 
and in vitro versus in vivo. 
3.3.4 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Cell 
Morphology in Co-Culture 
 Figure 3.11 shows representative fluorescence microscopy images of osteoclast (Raw 264.7 
cell line, 4000 cell/well) and osteoblast (7F2 cell line, 2000 cells/well) co-culture samples across 
multiple treatments corresponding to the 60% treatment variables from the co-culture viability 
study. Cytoskeletal actin is represented in green (FITC) and nuclei are represented in blue (DAPI). 
Multinucleated osteoclast cells are present in all samples. The arrow in Figures 3.11C, which 
corresponds to cells treated with which corresponds to ~1x1011 functionalized particles or ~0.5 µM 
for pamidronate, indicates a multinucleated osteoclast with disrupted nuclear morphology. Figure 
3.12 shows a representation of the different between healthy and unhealthy cells. This sample was 
the only sample where evidence of this disrupted morphology was present. No clear evidence of 
disrupted actin morphology was present in any of the samples.  
Osteoclasts can generally be distinguished from other bone cells by their large size and 
multiple nuclei [32] as seen in Figure 3.11. Figure 3.11 also shows smaller cells with single nuclei, 
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which are undifferentiated precursor cells. The presence of the mature osteoclasts supports the  
reasoning behind the use of a physiological co-culture, as the osteoblasts were the sole source of 
the RANKL that lead to the differentiation of the osteoclasts[33, 34]. Figure 3.11C shows a mature 
osteoclast with disrupted nucleus morphology (indicated by the arrow) and is similar to the results 
of study by Nicolin et al.[35]. This malformation is represented by the kidney bean shape to the 
nuclei rather than the typically circular or ellipsoidal shape present in healthy cells. All other 
treatments showed healthy cell morphology (indicated by arrows in all other images), being 
circular or ellipsoidal in shape. As nuclei of healthy cells are involved in protein synthesis among 
many other functions, disrupted morphology indicates compromised cell function.  These results 
are consistent with what has been reported previously about bisphosphonates disrupting 
morphology[1] and point out an additional means of modulating bone resorption rather than just 
through viability. 
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Figure 3.1 Schematic of experimental setup for osteoclast viability study. 
 
 
 
C 20% C 20% C 20% GP 40% GP 40% GP 40% P 60% P 60% P 60% Empty Empty Empty
G 20% G 20% G 20% GA 40% GA 40% GA 40% A 60% A 60% A 60% Empty Empty Empty
GP 20% GP 20% GP 20% P 40% P 40% P 40% C 100% C 100% C 100% Empty Empty Empty
GA 20% GA 20% GA 20% A 40% A 40% A 40% G 100% G 100% G 100% Empty Empty Empty
P 20% P 20% P 20% C 60% C 60% C 60% GP 100% GP 100% GP 100% Empty Empty Empty
A 20% A 20% A 20% G 60% G 60% G 60% GA 100% GA 100% GA 100% Empty Empty Empty
C 40% C 40% C 40% GP 60% GP 60% GP 60% P 100% P 100% P 100% Empty Empty Empty
G 40% G 40% G 40% GA 60% GA 60% GA 60% A 100% A 100% A 100% Empty Empty Empty
52 
 
 Figure 3.2 Effect of various treatments on osteoclast (Raw 264.7) viability after 72 hours. (A: top) 
Treatment with free pamidronate (P) and alendronate (A) compared with control (C). Here 100% 
treatment corresponds to 5 μM. (B: middle) Treatment with gold nanoparticles alone (G) and 
pamidronate functionalized nanoparticles (GP) compared with control (C). Here 100% treatment 
corresponds to ∼1.6 × 1011 particles and ∼0.8 μM pamidronate. (C: bottom) Treatment with gold 
nanoparticles alone (G) and alendronate functionalized nanoparticles (GA) compared with control 
(C). Here 100% treatment corresponds to ∼1.6 × 1011 particles and ∼3 μM alendronate. Asterisk 
denotes a significant difference P ≤0.05 relative to control. 
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Figure 3.3 Calibration curve for osteoclast viability study. 
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Figure 3.4 Effect of amiloride on osteoclast (Raw 264.7) viability after 24 hours. Amiloride 
toxicity on osteoclasts was assessed across ten serial dilutions of amiloride, with a maximum 
concentration of 40 µg/mL. Asterisk denotes a significant difference P ≤0.05 relative to the 
untreated control (C). 
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Figure 3.5 Schematic of experimental setup for osteoblast viability study. 
C 20% C 20% C 20% GP 40% GP 40% GP 40% P 60% P 60% P 60% Empty Empty Empty
G 20% G 20% G 20% GA 40% GA 40% GA 40% A 60% A 60% A 60% Empty Empty Empty
GP 20% GP 20% GP 20% P 40% P 40% P 40% C 100% C 100% C 100% Empty Empty Empty
GA 20% GA 20% GA 20% A 40% A 40% A 40% G 100% G 100% G 100% Empty Empty Empty
P 20% P 20% P 20% C 60% C 60% C 60% GP 100% GP 100% GP 100% Empty Empty Empty
A 20% A 20% A 20% G 60% G 60% G 60% GA 100% GA 100% GA 100% Empty Empty Empty
C 40% C 40% C 40% GP 60% GP 60% GP 60% P 100% P 100% P 100% Empty Empty Empty
G 40% G 40% G 40% GA 60% GA 60% GA 60% A 100% A 100% A 100% Empty Empty Empty
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Figure 3.6 Effect of various treatments on osteoblast (7F2) viability after 72 hours. (A: top) 
Treatment with free pamidronate (P) and alendronate (A) compared with control (C). Here 100% 
treatment corresponds to 2.5 μM. (B: middle) Treatment with gold nanoparticles alone (G) and 
pamidronate functionalized nanoparticles (GP) compared with control (C). Here 100% treatment 
corresponds to ∼0.8 × 1011 particles and ∼0.4 μM pamidronate. (C: bottom) Treatment with gold 
nanoparticles alone (G) and alendronate functionalized nanoparticles (GA) compared with control 
(C). Here 100% treatment corresponds to ∼0.8 × 1011 particles and ∼1.5 μM alendronate. Asterisk 
denotes a significant difference P ≤ 0.05 relative to control. 
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Figure 3.7 Calibration curve for osteoblast viability study. 
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Figure 3.8 Schematic of experimental setup for co-culture viability study. 
 
C 20% C 20% C 20% GP 40% GP 40% GP 40% P 60% P 60% P 60% Empty Empty Empty
G 20% G 20% G 20% GA 40% GA 40% GA 40% A 60% A 60% A 60% Empty Empty Empty
GP 20% GP 20% GP 20% P 40% P 40% P 40% C 100% C 100% C 100% Empty Empty Empty
GA 20% GA 20% GA 20% A 40% A 40% A 40% G 100% G 100% G 100% Empty Empty Empty
P 20% P 20% P 20% C 60% C 60% C 60% GP 100% GP 100% GP 100% Empty Empty Empty
A 20% A 20% A 20% G 60% G 60% G 60% GA 100% GA 100% GA 100% Empty Empty Empty
C 40% C 40% C 40% GP 60% GP 60% GP 60% P 100% P 100% P 100% Empty Empty Empty
G 40% G 40% G 40% GA 60% GA 60% GA 60% A 100% A 100% A 100% Empty Empty Empty
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 Figure 3.9 Effect of various treatments on osteoclast (Raw 264.7) and osteoblast (7F2) co-culture 
viability after 72 hours. (A: top) Treatment with free pamidronate (P) and alendronate (A) 
compared with control (C). Here 100% treatment corresponds to 5 μM. (B: middle) Treatment 
with gold nanoparticles alone (G) and pamidronate functionalized nanoparticles (GP) compared 
with control (C). Here 100% treatment corresponds to ∼1.6 × 1011 particles and ∼0.8 μM 
pamidronate. (C: bottom) Treatment with gold nanoparticles alone (G) and alendronate 
functionalized nanoparticles (GA) compared with control (C). Here 100% treatment corresponds 
to ∼1.6 × 1011 particles and ∼3 μM alendronate. Asterisk denotes a significant difference P ≤0.05 
relative to control. Pound sign denotes a significant difference P ≤0.05 between pairs. 
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Figure 3.10 Calibration curve for co-culture viability study. 
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Figure 3.11 Effect of various treatments on the morphology of osteoclast (Raw 264.7) cells in co-
culture after 72 hours. Treatments are noted as follows: control (A), gold nanoparticles alone (B), 
pamidronate functionalized nanoparticles (C), alendronate functionalized nanoparticles (D), free 
pamidronate (E), and free alendronate (F). Free bisphosphonate treatment concentrations were 3 
μM. All gold nanoparticle treatments corresponded to ∼1 × 1011 particles while the resulting 
concentration due to functionalized bisphosphonates corresponded to ∼0.48 μM pamidronate and 
∼1.8 μM alendronate. Arrows indicate osteoclast nuclei of interest and scale bar = 100 μm. 
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Figure 3.12 Schematic comparing difference in cell morphology of osteoclasts. 
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CHAPTER 4:  
CELL BEHAVIOR AND ACTIVITY1 
In this chapter, a detailed description is given on effects of bisphosphonate functionalized 
gold nanoparticles on important behavior and activity of osteoclast and osteoblast cells in vitro. 
The objective was to analyze the effect that functionalized nanoparticles have on expression of 
key proteins and enzymes in the osteoclast-osteoblast interplay. Additionally, the effect of surface-
modified nanoparticles on mineral deposition and bone resorption performance is also detailed. A 
number of different techniques were used to quantify RANKL and alkaline phosphatase expression 
in osteoblasts, as well as calcium deposition. Various staining and imaging techniques were used 
to observe calcium nodule formation and resorption pits in bovine bone slices.  
4.1 Introduction 
 Amino-bisphosphonates (n-BP) are considered the strongest clinical inhibitors of bone 
resorption, through their inhibition of hydroxyapatite breakdown[1, 2]. Various oral and IV 
bisphosphonates are FDA-approved for the treatment of many bone remodeling diseases, including 
osteoporosis, Paget disease, and Legg-Calve-Perthes[3-6]. Bisphosphonate therapy is the 
treatment of choice in osteoporosis, which is by far the most common clinical condition in which 
it is used. Increased risk of fracture is a hallmark of osteoporosis due to compromised bone strength 
and density. Paget disease of bone involves disordered bone remodeling, resulting from an 
1 Part of this chapter was published in Conners, Christopher M., Bhethanabotla, Venkat R., and Gupta, Vinay K. 
(2015). "Concentration-dependent effects of alendronate and pamidronate functionalized gold nanoparticles on 
osteoclast and osteoblast viability." J Biomed Mater Res B. Permission is included in Appendix B. 
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imbalance in osteoclast-mediated bone resorption and osteoblast-mediated bone deposition[7]. 
This often results in pain, fractures, and serious deformity. The application of bisphosphonate 
therapy leads to suppression of the accelerated bone resorption, which is considered the underlying 
cause of the disease.  
 Another consideration is the potential effect of bisphosphonates on osteoblasts. Osteoblasts 
express proteins that have been shown to be another major factor in the remodeling process of 
bone. Osteoblasts express receptor activator of nuclear factor (NF)-κB ligand (RANKL) as well as 
osteoprotegerin (OPG) that along with RANK, RANKL’s receptor expressed on OC cells, play a 
critical role in these three processes. RANKL binds with RANK expressed on the surface of pre-
osteoclast cells that promotes osteoclastogenesis[8]. OPG, expressed on the surface of osteoblasts, 
is a competitor protein to RANK that binds RANKL and helps to modulate this recruitment and 
differentiation process[9]. Modulation of the balance between the expression of OPG or RANKL, 
would therefore lead to modulation of osteoclastogenesis. 
 Furthermore, the exact effect of bisphosphonates on osteoblasts is not well agreed upon. In 
the context of bone formation, Orriss et al [10] performed a study where they tested the direct 
effect of unbound zoledronate, pamidronate and clodronate on primary rat osteoblast cells. They 
showed that with continuous treatment at concentrations as low as 10 nM, zoledronate was able to 
reduce bone mineralization. They also looked at the effect of zoledronate on osteoblasts cultured 
on dentine. Similar effects were seen, but at concentrations that were 10 to 100 fold greater. Idris 
et al. [11] saw similar results in their study, where they showed an inhibition of bone nodule 
formation at concentrations of 500 nM-1 µM for two bisphosphonates, namely pamidronate and 
alendronate. However, no inhibition for these concentrations was seen for etidronate and 
clodronate. Additionally, ALP and cell numbers were unaffected by any of these bisphosphonates 
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and at any of these concentrations. Idris et al. concluded that these results raise concern since these 
bisphosphonates caused osteoblast apoptosis as well as inhibited protein prenylation in a dose 
dependent manner in the range for 20-100 µM.  A different study by Knoch et al. [12] looked at 
the effect of bisphosphonates on bone marrow stromal cells (BMSC). BMSC are pluripotent cells 
that can differentiate into osteoblasts, adipocytes, fibroblasts and myocytes[13]. BMSC were 
acquire from patients undergoing total hip replacement therapy and cultured for use in their in vitro 
study. Their results showed an increase in proliferation of BMSC as well initiation toward 
osteoblastic differentiation when subjected to alendronate, risedronate and zoledronate, in a dose 
and time dependent manner.  
 Therefore, it is obvious that great consideration needs to be given to the concentrations that 
osteoblasts are subjected to in vivo and to the concentrations used when performing in vitro studies.  
4.2 Materials and Methods 
4.2.1 Materials 
Alendronate sodium trihydrate and pamidronate disodium salt hydrate were obtained from 
Sigma-Aldrich, St Louis, USA. Gold nanoparticle solutions were prepared as discussed in Chapter 
2. Raw 264.7 murine pre-osteoclast cells and 7F2 murine osteoblast cells were obtained from 
ATCC. Dulbecco's Modified Eagle's Medium (DMEM) (Cellgro, Mediatech, VA, USA) was 
supplemented with 10% (vol/vol) fetal bovine serum (Sigma) and 1% (vol/vol) antibiotic–
antimycotic (Sigma). Goat anti-mouse TRANCE/RANK L/TNFSF11, HRP-conjugated anti-goat 
secondary antibody, and recombinant mouse receptor activator of NF-κB ligand (RANKL) were 
obtained through R&D Systems (MN, USA). A Calcium Colorimetric Assay kit and an Alkaline 
Phosphatase Diethanolamine Activity Kit were obtained from Sigma as well. Protein bands were 
detected using chemiluminescence (LumiGLO; Cell Signaling) and imaged using a FluorChem E 
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System (ProteinSimple). Protein bands were quantified using image analysis software 
(AlphaView; ProteinSimple). All absorbance assays were read on a Synergy HT Microplate 
Reader from BioTek (Winooski, VT, USA).  
4.2.2 RANKL Differentiation of Raw 264.7 Pre-Osteoclast Cell Line 
Murine pre-osteoclast cells (RAW 264.7) were recovered from cryogenic storage in 1× 
DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine serum 
(Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% relative 
humidity. At approximately 80% confluence, the Raw 264.7 cells were cultured in media 
supplemented with 50 ng/ml of recombinant mouse receptor activator of NF-κB ligand, or 
RANKL, (R&D Systems, MN, USA) and allowed to incubate for eight days to encourage 
differentiation into mature osteoclasts. This protocol was applied in all studies where osteoclast 
cells were used unless otherwise noted.  
4.2.3 Western Blot for RANKL Expression 
The protein expression study was done in duplicate on the six groups noted above at a 
single treatment concentration. Murine osteoblast cells (7F2) were recovered from cryogenic 
storage in 1× DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal 
bovine serum (Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 
75% relative humidity. After allowing the cells to attach to the culture dish for 24 hours and 
subsequent treatment for 24 hours. The treatment concentrations were as follows: 1.5 µM for free 
pamidronate (P) and alendronate (A); 0.5x1011 particles for G, GP, and GA samples that is, 0.2 
µM for pamidronate (GP) and 0.9 µM alendronate (GA). The cells were then washed once with 
1x PBS and lysed using an SDS based lysis buffer supplemented with DTT and halt protease and 
phosphatase inhibitors. A total cell lysate (106 cells/mL) was sonicated to decrease viscosity, 
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heated at 95°C for 5 min and cooled on ice for 10 min. After centrifugation at 13,000 rpm for 1.5 
min, the lysates were separated using a 4%–12% Bis-Tris gel (1 hour at 150 V) and transferred to 
nitrocellulose membrane via an electrophoretic cell (1 hour at 350 mA).  
 Membranes were blocked with blocking buffer containing 5% (wt/vol) nonfat dry milk in 
TBST on a rocker platform for 1 hour at room temperature. Membranes were incubated with goat 
anti-mouse TRANCE/RANK L/TNFSF11 (0.25 ng/mL in 5% milk, R&D Systems) overnight at 
48°C. After being washed three times with TBST for 5 min each, the membranes were incubated 
with HRP-conjugated anti-goat (1:5,000 dilution in 5% nonfat dry milk, 1 hour at room 
temperature; R&D Systems). After being washed three times again, the protein bands were 
detected using chemiluminescence (LumiGLO; Cell Signaling) as per manufacturer’s instructions 
and imaged using a FluorChem E System (ProteinSimple). For loading control, the membranes 
were stripped using a stripping buffer (Thermo Scientific) for 30 min at room temperature and 
probed again for β-actin (Cell Signaling). Protein bands were quantified by densitometry using 
image analysis software (AlphaView; ProteinSimple) and were normalized to the intensity of β-
actin. 
4.2.4 Alkaline Phosphatase Expression 
 Murine osteoblast cells (7F2) were recovered in 1× DMEM (Cellgro, Mediatech, VA, 
USA) supplemented with 10% (vol/vol) fetal bovine serum (Sigma) and 1% (vol/vol) antibiotic–
antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% relative humidity. The osteoblasts were then 
seeded at a density of 3.2×104 cells/well in a 96-well plate. After allowing the cells to attach to the 
culture dish for 24 hours, the cells were treated with different variables as described below. 
 A 7 day study was conducted with six groups, each done in duplicate, and designated as 
follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells treated with 
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pamidronate functionalized GNP (GP), and cells treated with free pamidronate (P).  Each treatment 
was mixed with fresh medium before being added to the cells.  The untreated cells (C) served as 
the control. The treatment concentrations for the experiment were as follows: 1 µM for free 
pamidronate (P) and alendronate (A); ~0.3x1011 particles for G, GP, and GA, that is, ~0.2 µM for 
functionalized pamidronate (GP) and ~0.6 µM for functionalized alendronate (GA). In the case of 
samples treated with gold nanoparticle systems, treatment with 10 μL of nanoparticle solution was 
used. These concentrations correspond to the toxicity thresholds that resulted from earlier viability 
studies discussed in Chapter 3. By staying at or below the toxicity threshold, we expect to remove 
viability as a variable. A separate control was used for each group so that the volume ratio of 
treatment to medium was maintained. 
 At the end of the treatment period, the spent culture media was removed and the cells were 
rinsed with 1x PBS.  The cells were then lysed with 50 µL of DI water through a freeze/thaw cycle. 
The ALP expression was then quantified through the use of the Alkaline Phosphatase 
Diethanolamine Activity Kit from Sigma following their protocol. The protocol was amended by 
scaling down for use in a 96-well plate. Absorbance was read on a Synergy HT Microplate Reader 
from BioTek (Winooski, VT, USA). 
4.2.5 Calcium Deposition Quantification 
Murine pre-osteoclast cells (RAW 264.7) and murine osteoblast cells (7F2) were recovered 
in 1× DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine 
serum (Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% 
relative humidity. For the mono-culture study, the osteoblasts were seeded at a density of 2×103 
cells/well. For the co-culture study, the undifferentiated Raw 264.7 cells and the osteoblasts were 
seeded together (co-culture) at a density of 4×103 cells/well and 2×103 cells/well respectively in 
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96-well plates. Note that the Raw 264.7 cells were not differentiated with RANKL prior to seeding 
as the 7F2 osteoblast cells express RANKL and this co-culture was intended to reflect 
physiologically relevant conditions. These seeding densities allow for comparable particle/cell 
concentrations as seen in the mono-culture experiments. After allowing the cells to attach to the 
culture dish for 24 hours, the cells were treated with different variables as described below. 
Two different 7 day studies were conducted with four groups, each done in duplicate, and 
designated as follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells 
treated with pamidronate functionalized GNP (GP), and cells treated with free pamidronate (P).  
Each treatment was mixed with fresh medium before being added to the cells.  The untreated cells 
(C) served as the control. The treatment concentrations for the mono-culture experiment were as 
follows: 1 µM for free pamidronate (P); ~0.3x1011 particles for G, and GP, that is, ~0.2 µM for 
functionalized pamidronate (GP). The treatment concentrations for the co-culture experiment were 
as follows: : 3 µM for free pamidronate (P); ~1x1011 particles for G, and GP, that is, ~0.5 µM for 
functionalized pamidronate (GP). In the case of samples treated with gold nanoparticle systems, 
treatment with 10 and 30 μL of nanoparticle solution was used for the mono-culture and co-culture 
respectively. These concentrations correspond to the toxicity thresholds that resulted from earlier 
viability studies discussed in Chapter 3. By staying at or below the toxicity threshold, we expect 
to remove viability as a variable. A separate control was used for each group so that the volume 
ratio of treatment to medium was maintained. 
At the end of the treatment period, the spent culture media was removed and the cells were 
rinsed with 1x PBS.  50 µL of 5% TCAA was then added to each well in order to dissolve the 
calcium over a 90 minute period in an incubator. The dissolved calcium was the quantified through 
the use of the Calcium Colorimetric Assay kit from Sigma following the protocol that was 
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specified by the kit. Absorbance was read on a Synergy HT Microplate Reader from BioTek 
(Winooski, VT, USA). A calibration curve was produced per the manufacturer’s directions and all 
results were found to be within the range and linear region of the curve (Figure 4.8).  
4.2.6 Calcium Staining 
Murine pre-osteoclast cells (RAW 264.7) and murine osteoblast cells (7F2) were recovered 
in 1× DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine 
serum (Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% 
relative humidity. For the mono-culture study, the osteoblasts were seeded at a density of 2×104 
cells/well. For the co-culture study, the undifferentiated Raw 264.7 cells and the osteoblasts were 
seeded together (co-culture) at a density of 4×104 cells/well and 2×104 cells/well respectively in 
6-well plates. Note that the Raw 264.7 cells were not differentiated with RANKL prior to seeding 
as the 7F2 osteoblast cells express RANKL and this co-culture was intended to reflect 
physiologically relevant conditions. These seeding densities allow for comparable particle/cell 
concentrations as seen in the mono-culture experiments. After allowing the cells to attach to the 
culture dish for 24 hours, the cells were treated with different variables as described below. 
Two different 7 day studies were conducted with four groups, each done in duplicate, and 
designated as follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells 
treated with pamidronate functionalized GNP (GP), and cells treated with free pamidronate (P).  
Each treatment was mixed with fresh medium before being added to the cells.  The untreated cells 
(C) served as the control. The treatment concentrations for the mono-culture experiment were as 
follows: 1 µM for free pamidronate (P); ~0.3x1012 particles for G, and GP, that is, ~0.2 µM for 
functionalized pamidronate (GP). The treatment concentrations for the co-culture experiment were 
as follows: : 1 µM for free pamidronate (P); ~1x1012 particles for G, and GP, that is, ~0.5 µM for 
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functionalized pamidronate (GP). In the case of samples treated with gold nanoparticle systems, 
treatment with 100 and 300 μL of nanoparticle solution was used for the mono-culture and co-
culture respectively. These concentrations correspond to the toxicity thresholds that resulted from 
earlier viability studies discussed in Chapter 3. By staying at or below the toxicity threshold, we 
expect to remove viability as a variable. A separate control was used for each group so that the 
volume ratio of treatment to medium was maintained.  
At the end of the 7 day treatment period cells were fixed with p-formaldehyde at room 
temperature for 10 minutes. After rinsing twice with 1x PBS, cells were treated with 2% alizarin 
red solution (pH 4.2 using 0.5% ammonium hydroxide) for 30 minutes. The cells were then 
thoroughly rinsed to remove any residue and imaged via optical microscopy.  
4.2.7 Bone Resorption 
Bovine bone slices (Immunodiagnostic Systems, Gaithersburg, MD, US) were first 
prepared by rinsing with supplemented DMEM and allowed to soak for half an hour on the last 
rinse in order to remove any remaining ethanol. The slices were then place, one in each well, in a 
96 well plate prior to seeding with cells.  
RANKL-differentiated Raw 264.7 cells were seeded at a density of 4×103 cells/well in the 
96-well plate containing the bovine bone slices. After allowing the cells to attach for 24 hours, the 
cells were treated with the different variables as described. 
Resorption was allowed to take place over 5 days with four groups, each done in duplicate, 
and designated as follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells 
treated with pamidronate functionalized GNP (GP), and cells treated with free pamidronate (P). 
Each treatment was mixed with fresh medium before being added to the cells.  The untreated cells 
(C) served as the control.  For the free pamidronate, osteoclasts were treated with 1 and 5 μM. In 
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the case of samples treated with gold nanoparticle systems, treatment with 10 and 50 μL of 
nanoparticle solution was used. In each case, the 50 μL volume i.e. the highest treatment 
concentration, corresponded to ~4x107 nanoparticles/cell.   A separate control was used for each 
group so that the volume ratio of treatment to medium was maintained. At the end of the 5 day 
treatment period, an enzyme-linked immunosorbent assay (ELISA) was used to quantify type I 
collagen in the cell culture supernatants using a CrossLaps® for Culture (CTX-I) ELISA kit from 
Immunodiagnostic Systems following the manufacturers protocol and the assay was analyzed on 
a Synergy HT Microplate Reader from BioTek (Winooski, VT, USA). A calibration curve was 
produced per the manufacturer’s directions and all results were found to be within the range and 
linear region of the curve (Figure 4.10). 
Pit formation was confirmed at the completion of the study. Briefly, cells were rinsed with 
1x PBS and then removed from the bone slices through lysis and sonication using DI water. After 
removal of the lysate, 100 µL of toluidine blue (1% dissolved in DI water) was added to each well 
and allowed to stain for 1 minute at room temperature. The slices were then rinsed a minimum of 
5 times with 250 µL of DI water in order to wash out any residue. Resorption pits were then imaged 
with an EVOS FL Cell Imaging System from Invitrogen.  
4.2.8 Statistical Analysis 
Statistical results are expressed as means +/- SD. Comparisons between data were made 
with the use of student’s t-test where significance was determined at p ≤ 0.05. 
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4.3 Results and Discussion 
4.3.1 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Protein 
Expression in Osteoblasts 
Figure 4.1 shows the results of the western blot analysis of RANKL expression relative to 
b-Actin in the osteoblast cell line. Figure 4.2 shows the corresponding quantitative analysis of the 
expression of RANKL relative to β-Actin (P ≤ 0.05). As was previously discussed, RANKL is a 
key protein involved in the communication between OB and OC cells and has been shown to be 
integral in the bone remodeling process. The results of the western blots, Figures 4.1 and 4.2 show 
that there is no effect on RANKL expression in OB cells when treated with the nanoparticles alone 
(G) or pamidronate functionalized nanoparticles (GP). However, the results do show an increase 
in expression when the cells are treated with GA, P and A, relative to the control.  
These results are in general agreement with what has been previously reported in the 
literature[14, 15]. Ultimately, these results support that for concentrations at or below the toxicity 
threshold, as revealed by the viability studies in Chapter 3, the expression of RANKL is not 
impacted by our bisphosphonate functionalized gold nanoparticles. This is an important 
consideration when looking at the impact of a potential new treatment, as other changes to normal 
cell behavior or performance may result in ultimately the same result as decreased viability. 
Maintaining viability in osteoblasts, while decreasing their normal functions, may ultimately still 
be a net negative result in relation to shifting the balance of the remodeling process. 
Additionally, an investigation into the effect of our nanoparticles systems on the expression 
of OPG was also attempted. OPG, expressed on the surface of osteoblasts, is a competitor protein 
to RANK that binds RANKL and helps to modulate this recruitment and differentiation process[9], 
so it would be insightful to understand this relationship. The results of the study were ultimately 
74 
 
inconclusive as the OB cell line used in this study did not appear to express sufficient OPG, when 
using a positive control to confirm. The 7F2 (CRL-12557 from ATCC) cell line is generally 
classified as a mature osteoblast cell line because it has been shown to express alkaline 
phosphatase, secrete type I collagen, show a significant cyclic adenosine monophosphate response 
to parathyroid hormone, secrete osteocalcin, and mineralize extensively. It is a spontaneously 
immortalized cell line isolated from p53-/- mouse bone marrow taken from the femur and 
subsequently cloned[16]. This is an example of the difficulty with in vitro studies, as the results 
can vary widely based on a number of factors, including cell lines that are not primary. Further 
investigation into the effect of bisphosphonate functionalized gold nanoparticles on this 
OPG/RANKL system would be of interest. 
4.3.2 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Alkaline 
Phosphatase Expression  
Figure 4.3 shows the results of the alkaline phosphatase assay with values relative to 
control (C, P ≤ 0.05). The results show that there is no difference across all treatments when 
compared to the control. This is supported in the literature for the concentration range studied in 
the experiment[17]. The concentrations used in this study should eliminate viability as a variable 
based on the results presented in Chapter 3. Alkaline phosphatase is an enzyme which is attached 
to the outer face of the plasma membrane (an ectoenzyme) in vertebrates[18]. Humans have four 
ALP genes including one that corresponds to liver/bone/kidney gene products [19], which is 
classified as tissue non-specific. The role of ALP in bone mineralization was first proposed more 
than 8 decades ago, and is well established today. ALP acts through a catalytic mechanism to 
increase the local concentration of inorganic phosphate[20]. Additionally, mineralization of the 
new bone tissue has been repeated shown to be preceded by measurement of high levels of ALP 
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expression, during the pursuit of novel tissue engineering constructs[21-23]. The results here 
support the notion that if a concentration is targeted that does not affect cell viability, it can also 
be expected to not affect other key behavior, specifically, expression of alkaline phosphatase. This 
indicates that normal osteoblast performance for bone mineralization could be maintained. 
4.3.3 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Bone Nodule 
Formation 
Figure 4.4 shows the results of the calcium quantification analysis of bone nodule 
formation by the osteoblast cell line in mono-culture relative to control (P ≤ 0.05). Figure 4.5 
shows the complementary alizarin red staining of the bone nodule formation in vitro, where the 
arrows indicate bone nodule formations. Alizarin red reacts with calcium, resulting in a red/orange 
stain, thereby identifying calcium deposits[24]. The results of the quantitative analysis in Figure 
4.4 show that there is no effect on bone nodule formation by OB cells across all treatment variables 
at the concentrations studied. This is supported by past study by Orriss et al [10], where they also 
saw no decrease in nodule formation with 1 µM pamidronate. As discussed before, the 
concentrations used in this study should eliminate viability as a variable based on the results 
presented in Chapter 3 and this is supported by these results. The results in Figure 4.4 are also 
supported by the images in Figure 4.5, where no qualitative difference can be determined. The 
arrows in Figure 4.5 indicate a few examples of bone nodules, which show as strong orange/red 
color. Additionally, this is in agreement with the previously discussed ALP expression study, 
which would be consistent with no change in mineralization behavior.  
Figure 4.6 shows the results of the calcium quantification analysis of bone nodule 
formation by the osteoblast cell line in co-culture with the osteoclast cell line, relative to control 
(P ≤ 0.05). Figure 4.7 shows the complementary alizarin red staining of the bone nodule formation 
76 
 
in vitro. Similar to the results in Figure 4.5, Figure 4.6 also shows that there is no effect on bone 
nodule formation by OB cells across all treatment variables at the concentrations studied, when 
co-cultured with osteoclasts. This is supported by the images in Figure 4.7, where no qualitative 
difference can be determined. However, by comparing Figure 4.5 and 4.6, it is obvious that the 
inclusion of the osteoclasts affects the degree of mineralization. The bone nodules in each figure 
differ significantly (see arrows for guidance). The nodules in Figure 4.5 are larger and more 
concentrated (indicated by strong staining) than those in Figure 4.6. This is a good representation 
of the bone remodeling process and the balance between bone deposition and bone resorption. As 
the OB cells are mineralizing, the OC cells are simultaneous resorbing, producing less distinct 
nodule formation and wider distribution of calcium throughout the plate.  
4.3.4 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Bone 
Resorption 
 Figure 4.9 shows the results of the analysis of bone resorption on bovine bone slices by 
osteoclasts, via quantification of type I collagen in the cell supernatant, when treated with two 
different concentrations. As discussed previously, osseous tissue is made up of various inorganic 
salts as well as collagen[25]. Type I collagen accounts for more than 90% of the organic matrix of 
bone, fragments of which are released during the bone remodeling process. Note that these 
treatment concentrations correspond to the lowest and highest concentrations investigated in the 
osteoclast viability study discussed in Chapter 3. Figure 4.11 is a representative image of 
confirmation of resorption pit formation through toluidine blue staining. The results in Figure 4.9 
indicated that there is no difference in any treatment compared to its control (P ≤ 0.05) with the 
exception of the 5 µM free bisphosphonate treatment. The 1 µM treatments agree with the viability 
data presented in Chapter 3 which showed no decrease in cell viability, as a decrease in viability 
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should correspond to a decrease in bone resorption. However, the 5 µM treatment does not agree 
with the previous viability data. That viability data showed a decrease in cell viability when treated 
with the corresponding pamidronate functionalized GNP. However, it is important to note that the 
viability was not considered in the presence of bone.   
Bisphosphonates have been shown to be readily attracted to and strongly adherent to 
bone/hydroxyapatite[26]. This feature has even been leveraged as a targeting method for 
microcalcifications in breast tissue for contrast enhanced X-ray[27, 28]. With the potential 
interaction between the bisphosphonates, both on the surface of the gold and in free form, this may 
lead to a change in the uptake of the pharmaceutical in the presence of bone. The significantly lower 
concentration of bisphosphonate on the surface of the gold as determine through ICP-MS discussed 
in Chapter 2 may have ultimately led to the difference seen in this study. As the osteoclasts resorb 
the bone surface and uptake bisphosphonate that may be interacting with the bone, the advantage 
may conceivably be with the treatment having higher total bisphosphonate availability, which in 
this case would be the 5 µM free bisphosphonate treatment over the ~3 µM bound bisphosphonate 
in the pamidronate functionalized gold nanoparticle treatment. This premise is supported in the 
literature. A study by Schindeler et al. [29] where they cultured osteoblasts and osteoclast separately 
on phosphate coated quartz disks that were pretreated with zoledronic acid, showed that although 
osteoclasts were negatively influenced by this substrate, osteoblasts were largely unaffected. In fact, 
they went on to proliferate, and produce a mineralized matrix. Similar results were shown by 
Panzavolta et al.[30]. This adherence to bone surfaces could act as an additional avenue for uptake 
in OC cells, as only OC cells resorb the bone surface. This strong interaction with bone is an 
important consideration in further developing potential treatments for osteoporotic disease. 
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Figure 4.1 Western blot results (in duplicate) of RANKL and β-actin expression in osteoblast cells. 
The treatment concentrations were as follows: 1.5 µM for free pamidronate (P) and alendronate 
(A); 0.5x1011 particles for G, GP, and GA samples that is, 0.2 µM for pamidronate (GP) and 0.9 
µM alendronate (GA). 
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Figure 4.2 Quantitative analysis of the expression of RANKL relative to β-actin from the western 
blot. The treatment concentrations were as follows: 1.5 µM for free pamidronate (P) and 
alendronate (A); 0.5x1011 particles for G, GP, and GA samples that is, 0.2 µM for pamidronate 
(GP) and 0.9 µM alendronate (GA). Asterisk denotes a significant difference P ≤ 0.05 relative to 
control. 
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Figure 4.3 Quantitative analysis of the expression of ALP by osteoblasts. The treatment 
concentrations were as follows: 1 µM for free pamidronate (P) and alendronate (A); ~0.3x1011 
particles for G, GP, and GA, that is, ~0.2 µM for functionalized pamidronate (GP) and ~0.6 µM 
for functionalized alendronate (GA). Values were compared to control (C, P ≤ 0.05). 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
C G GP GA P A
AL
P 
Ex
pr
es
si
on
 R
el
at
iv
e 
to
 C
on
tr
ol
Sample
84 
 
  
 
 
Figure 4.4 Quantitative analysis of the bone nodule formation in mono-culture of osteoblasts.  
Bone nodule formation was quantified through the quantification of calcium present in each 
sample. The treatment concentrations were as follows: 1 µM for free pamidronate (P); ~0.3x1011 
particles for G, and GP, that is, ~0.2 µM for functionalized pamidronate (GP). Values were 
compared to control (C, P ≤ 0.05). 
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Figure 4.5 Alizarin red staining of bone nodule formation in mono-culture of osteoblasts at 10x 
magnification.  Arrows indicate some of the nodule formations. Measure dot indicates 150 µm. 
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Figure 4.6 Quantitative analysis of the bone nodule formation in co-culture of osteoblasts with 
osteoclasts. Bone nodule formation was quantified through the quantification of calcium present 
in each sample. The treatment concentrations were as follows: 3 µM for free pamidronate (P); 
~1x1011 particles for G, and GP, that is, ~0.5 µM for functionalized pamidronate (GP).Values were 
compared to control (C, P ≤ 0.05). 
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Figure 4.7 Alizarin red staining of bone nodule formation in co-culture of osteoblasts with 
osteoclasts at 5x magnification. Arrows indicate some of the nodule formations. Measure dot 
indicates 150 µm. 
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Figure 4.8 Calibration curve for calcium colorimetric assays. 
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Figure 4.9 Quantitative analysis of the bone resorption by osteoclasts. Bone resorption was 
analyzed by quantification of type I collagen release from bovine bone slices due to resorption. 
Here 100% treatment corresponds to 5 μM free pamidronate (P), ∼1.6 × 1011 particles gold 
nanoparticles alone (G) and pamidronate functionalized nanoparticles (GP), which corresponds to 
∼0.8 μM pamidronate on gold (GP). Asterisk denotes a significant difference (P ≤0.05) relative to 
control (C). 
 
 
*
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
20% 100%
Ty
pe
 I 
Co
lla
ge
n 
Co
nc
en
tr
at
io
n 
Re
la
tiv
e 
to
 C
on
tr
ol
Treatment Concetrations
Bone Resorption Assay via ELISA
C
G
GP
P
90 
 
  
 
 
 
Figure 4.10 Calibration curve for ELISA assay of bone resorption. 
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 Figure 4.11 Representative image of resorption pit formation. Pit formation on bovine bone slices 
was confirmed via toluidine blue staining. Figure A was not seeded with osteoclasts and shows a 
lack of resorption pits. Arrows in Figure B indicate some of the resorption pits formed by 
osteoclasts. Image is at 10x magnification and measure bar indicates 400 µm. 
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CHAPTER 5:  
SUMMARY, CONCLUSIONS AND FUTURE WORK 
5.1 Summary and Conclusions 
In this doctoral research, we have synthesized and studied the effect of bisphosphonate 
functionalized gold nanoparticles on in vitro cell cultures, toward the development of a potential 
new treatment and means of study, for osteoporotic bone disease. First, we synthesized and 
characterized the bisphosphonate functionalized gold nanoparticles, including quantification of 
bound bisphosphonates on the surface of the gold. We then took a look at the effect of these 
bisphosphonate functionalized gold nanoparticles on cell viability and morphology compared to 
free bisphosphonate delivery. Finally, we analyzed the effect of these gold nanoparticle systems 
on other key cell behavior and activity, including protein expression and bone remodeling.   
In Chapter 2, a detailed description was given on the synthesis and characterization of 
bisphosphonate functionalized gold nanoparticles. Gold nanoparticles were synthesized with size 
of approximately 15 nm, which are suitable for cellular uptake, and then the surface was 
functionalized using self-assembly, with pamidronate and alendronate. Microscopy, spectroscopy, 
and scattering techniques were used to gain insight into the particle size distribution, shape, and to 
help confirm surface modification with bisphosphonates. In an important advance compared to 
past studies, inductively coupled plasma mass spectrometry was used to measure the surface 
density of the bisphosphonates on the gold nanoparticles, being approximately 0.65 molecules per 
nm2 (approximately 154 Å2/molecule) for GP and approximately 2.6 molecules per nm2 
(approximately 39 Å2/molecule) for GA. This allows for more accurate estimates of 
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pharmaceutical concentrations, when comparing to free bisphosphonates, which is important when 
comparing results of in vitro and in vivo studies.  
In Chapter 3, we investigated the effects of bisphosphonate functionalized gold 
nanoparticles on the viability and morphology of osteoclast and osteoblast cells in vitro. The 
various in vitro studies included mono-cultures of osteoclasts and of osteoblasts as well as more 
physiologically relevant co-cultures that relied on the RANKL expression of osteoblasts to 
differentiate the Raw 264.7 pre-osteoclast cells.  We found that attaching the bisphosphonates to 
the surface of the nanoparticles leads to increased apoptotic effects of the bisphosphonates on the 
osteoclast cells compared to free bisphosphonates. This is important, as the surface density 
discussed in Chapter 2 shows that we have much lower concentrations of bisphosphonates when 
bound to the surface of the gold. This result is likely explained by the endocytotic nature of 
osteoclasts. Further, we showed bisphosphonate functionalized gold nanoparticles may have an 
effect on nuclei morphology, which may provide an additional means of modulating bone 
resorption rather than just through viability. Finally, we showed that it may be possible to target a 
concentration that is safe for osteoblasts, which is critical in determining potential treatment 
concentrations. However, it is clear that under more physiologically accurate conditions, these 
results are much more difficult to separate. These viability results bring to light a number of 
potential considerations in the optimization of potential treatments, such as dosing and in vitro 
versus in vivo concentrations.   
Chapter 4 detailed results on effects of bisphosphonate functionalized gold nanoparticles 
on important behavior and activity of osteoclast and osteoblast cells in vitro. The objective was to 
analyze the effect that functionalized nanoparticles have on expression of key proteins and 
enzymes in the osteoclast-osteoblast interplay. Additionally, the effect surface-modified 
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nanoparticles have on mineral deposition and bone resorption performance was also detailed. A 
number of different techniques were used to quantify RANKL and alkaline phosphatase expression 
in osteoblasts, as well as calcium deposition. Various staining and imaging techniques were used 
to observe calcium nodule formation and resorption pits in bovine bone slices. We showed that 
while using concentrations below the toxicity threshold, some of the normal activity of the cells 
could be maintained. RANKL and ALP expression in osteoblasts were maintained when removing 
viability as a variable. Additionally, bone nodule formation was also maintained for osteoblasts 
and co-cultured in vitro systems. Finally, we showed that the introduction of bone in the in vitro 
studies adds a new degree of consideration as to the interaction of the bisphosphonates with the 
hydroxyapatite surface. This strong interaction with bone is an important consideration in further 
developing potential treatments for osteoporotic disease. 
Overall, this dissertation provides insights into the use of bisphosphonate functionalized 
gold nanoparticles as a potential treatment and means of study for bone remodeling disorders. In 
addition, this dissertation has helped to highlight the different considerations necessary when 
studying a potential new treatment.  
5.2 Future Work 
We believe that the research pursued in this doctoral project lays the groundwork for future 
work on the development of gold nanoparticle based treatments for osteoporotic disease. 
Throughout this dissertation, we discussed a number of important considerations moving forward 
to the development of a potential treatment. Some of these considerations include: 
• concentrations comparisons in vitro versus in vivo  
• cell lines used in in vitro studies 
• the stability of these nanoparticle systems in vitro and in vivo 
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• the effect bisphosphonate interaction with bone plays in the deployment of 
bisphosphonate functionalized gold nanoparticles as a treatment 
Towards these ends, we present the following considerations for potential future work.  
In Vitro studies are a good way to lay the foundation for any new treatment. However, the 
logical next step would be studies involving animal models. These investigations would address 
many of the previously describe issues. Differences in cell lines would no longer be a concern. 
Although, we would still ultimately contend with the issue of translating disease treatment from 
animal model to human, eventually. Furthermore, animal models would allow for significantly 
greater physiological complexity than could be achieved in any in vitro study. It would also allow 
more direct investigation into local concentrations in vivo and address the issue of having to 
translate in vitro concentrations to what is experienced in vivo. The application of similar 
bisphosphonate functionalized gold nanoparticles has been shown in detection of breast 
microcalcifications using contrast-enhanced X-ray when injected into a murine model of breast 
cancer [1, 2]. There are a number of animal models available for the study of osteoporosis, which 
have been vetted thoroughly in the literature[3]. Ultimately, investigation of the effects of 
bisphosphonate functionalized gold nanoparticles in vivo would go the furthest in addressing many 
of the issues discussed in this dissertation. 
There remains a concern with the stability of the bisphosphonate functionalized gold 
nanoparticles as designed. Due to the relatively weak interaction between the primary amine group 
of the bisphosphonates and the surface of the gold [4, 5], introduction into an in vivo system may 
lead to instability. This would likely be cause by extracellular components in the blood stream or 
tissue after introduction into the body. Additionally, if we were able to increase the residence time, 
we may be able to decrease dosing frequency and concentration. A promising way of approaching 
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these issues is through the application of a biodegradable polymer coating. Some studies have 
shown promising results with the incorporation of SPIO in biodegradable polymer for magnetic 
resonance imaging [6-8], which can conceivably be applied to our GNP systems. PEGylation, 
which is the modification of nanoparticle surfaces by the addition of polyethylene glycol (PEG), 
is the most commonly used method for reducing premature clearance of NPs from the body[9]. 
This approach is typically termed “stealthing”. An additional benefit of PEGylation and other 
similar polymer coating approaches, is the ability to load the pharmaceutical of interest in the 
polymer[10]. The drug is released as the polymer degrades, and has the added benefit of 
significantly stabilizing the nanoparticle system. The modification of our gold nanoparticle system 
by addition of a polymer coating would be beneficial next step toward a potent new treatment.  
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Appendix A: List of Abbreviations 
GNP   Gold nanoparticle 
LSPR  Localized surface plasmon resonance 
DMEM   Dulbecco’s modified eagle medium 
PBS   Phosphate buffer saline 
FBS   Fetal bovine serum 
DLS   Dynamic light scattering 
BP   Bisphosphonate 
nBP   Nitrogen containing bisphosphonate 
ALN   Alendronate 
PAM   Pamidronate 
RANK   Receptor activator of nuclear factor kappa-B 
RANKL   Receptor activator of nuclear factor kappa-B ligand 
MTT   Methylthiazol tetrazolium 
OPG   Osteoprotegerin 
OC   Osteoclast 
OB   Osteoblast 
ALP  Alkaline phosphatase 
ICP-MS  Inductively coupled plasma mass spectrometry 
ELISA  Enzyme-linked immunosorbent assay 
UV-vis  Ultra violet – visible 
PEG  Polyethylene glycol 
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